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This comprehensive State of the Art review summarizes the current
published knowledge base regarding the pathophysiology and mi-
crobiology of pulmonary disease in cystic fibrosis (CF). The molecu-
lar basis of CF lung disease including the impact of defective cystic
fibrosis transmembrane regulator (CFTR) protein function on air-
way physiology, mucociliary clearance, and establishment of Pseu-
domonas aeruginosa infection is described. An extensive review of
the microbiology of CF lung disease with particular reference to
infectionwithP.aeruginosaisprovided.Otherpathogenscommonly
associated with CF lung disease including Staphylococcal aureus,
Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter
xylosoxidans and atypical mycobacteria are also described. Clinical
presentationandassessmentofCFlungdiseaseincludingdiagnostic
microbiology and other measures of pulmonary health are re-
viewed. Current recommendations for management of CF lung dis-
ease are provided. An extensive review of antipseudomonal thera-
pies in the settings of treatment for early P. aeruginosa infection,
maintenance for patients with chronic P. aeruginosa infection, and
treatment of exacerbation in pulmonary symptoms, as well as anti-
biotic therapies for other CF respiratory pathogens, are included.
In addition, the article discusses infection control policies, therapies
to optimize airway clearance and reduce inflammation, and poten-
tial future therapies.
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The cystic ﬁbrosis (CF) scientiﬁc community has orchestrated
a focused, multidisciplinary effort to understand the molecular
basis of this disorder and at the same time improve clinical care
for patients with CF. After identiﬁcation of the CF gene in
1989, the 1990s was a decade associated with rapid expansion
of knowledge regarding the structure and function of the CF
gene product, CF transmembrane conductance regulator (CFTR)
protein. The previous State of the Art assessment of CF in 1996
(1) provided a comprehensive review focusing on signiﬁcant
advances in scientiﬁc understanding of the CFTR gene. As we
enter the 21st century, both laboratory and clinical investigators
are applying this knowledge toward elucidating the critical fac-
tors that initiate chronic endobronchial bacterial infection in this
genetic disorder and are using this knowledge to develop novel
and effective therapies. This State of the Art focuses on the
current understanding of the impact of abnormal CFTR function
on airway surface liquid (ASL) that initiates a pathophysiologic
cascade leading to progressive lung disease. The role of chronic
endobronchial bacterial infection with pathogens such as Pseu-
domonas aeruginosa and the resultant intense neutrophilic in-
ﬂammatory response, pathognomonic for this lung disease, will
be reviewed. In addition, current and future therapies to control
or eradicate Pseudomonas infection and slow disease progres-
sion are summarized. This review focuses only on the pulmonary
aspects of this genetic disease and does not include other impor-
tant aspects of this illness including gastrointestinal, endocrine,
and metabolic manifestations of CF (2).
CF is an autosomal recessive disorder caused by mutations in
a single gene on the long arm of chromosome 7 that encodesState of the Art 919
Figure 1. Median survival age in cystic fibrosis, 1985–2001. Data from
the U.S. Cystic Fibrosis Foundation Patient Registry showing the age of
expected death for 50% of the current Registry population, given the
ages of the patients in the Registry and the mortality distribution of
deaths for that specific year. The 95% confidence intervals for the survival
estimate are denoted by the vertical bars. The median estimated survival
is 33.4 years for 2001. (Reprinted by permission from Reference 6.)
the CFTR protein (2–5). Despite impressive advances in under-
standing the molecular basis and pathophysiology of this disor-
der, it remainsthe most common life-shorteninggenetic disorder
in the white population with an estimated median survival age
of 33.4 years in the United States in 2001 (Figure 1). This repre-
sents an increase of 6 years since the previous State of the Art
was written (6). CF affects approximately 30,000 individuals in
the United States and 60,000 individuals worldwide with an esti-
mated incidence in the U.S. white population ranging from 1 in
1,900 to 1 in 3,700 (2, 7). CF is present, but less frequent, in
Hispanic (8), Asian (9), and African American (7, 10) popula-
tions (1 in 9,000, 1 in 32,000, and 1 in 15,000, respectively). The
CF gene is large, spans 250 kb, and is composed of 27 exons
(11). As shown in Figure 2, the gene is transcribed into a 6.5-kb
messenger RNA (3) that encodes a 1,480 amino acid protein.
Since identiﬁcation of the gene, over 800 disease-associated mu-
tations in the CF gene have been reported to the CF Genetic
Analysis Consortium database (www.genet.sickkids.on.ca/cftr/).
The vast majority of mutations involves three or fewer nucleo-
tides and result in predominantly amino acid substitutions,
frameshifts, splice site, or nonsense mutations.
Although a large number of CF-causing mutations have been
described, only 22 mutations have been identiﬁed with a fre-
quency of at least 0.1% of known alleles (12). The remaining
mutations are extremely rare and often limited to one or a few
individuals. The most common and ﬁrst identiﬁed mutation, a
three base pair deletion that codes for phenylalanine at position
508 of the CFTR protein, F508, accounts for 70% of CF alleles
in whites (13). It is the presence of F508 that increases the
frequency of CF in the white population relative to other races.
Although several theories have been proposed suggesting a se-
lective advantage for F508 heterozygotes such as resistance to
secretory diarrhea from cholera (14) or protection against bron-
chial asthma (15), no conﬁrmatory data are available. The other
21 common mutations are often found in higher frequency in
particular ethnic groups, such as the W1282X mutation in Aske-
nazi Jewish populations (16), G551D in French Canadians (17),
and 3,120  1G → A in African/Mediterranean populations (18).
In vitro physiologic studies have demonstrated that mutations
in the CF gene can disrupt CFTR function within epithelial
cells in different ways, ranging from complete loss of protein to
surface expression with poor chloride conductance (19). The
ﬁve major mechanisms by which CFTR function is altered are
summarized in Figure 3. Class I mutations produce premature
transcriptiontermination signalsresultingin unstable,truncated,
or no protein expression. Class II mutations, usually missense
mutations including F508, cause the protein to misfold leading
to premature degradation and failure to reach the apical cell
membrane except for special conditions such as low temperature
(20). Class III mutations, primarily located in the two nuclear-
binding domains, result in decreased chloride channel activity
(21) due to abnormal adenosine triphosphate (ATP) gating.
Class IV mutations are primarily located in the membrane span-
ning domains that form the chloride channel and demonstrate
reduced chloride conductance (22). Class V mutations result in
reduced amounts of functional protein (rather than no protein
production seen in Class I) due to abnormal or alternative splic-
ing (23). It is important to recognize that speciﬁc mutations may
have characteristics of more than one class. Thus, these ﬁve
mechanisms of CFTR dysfunction are intended to provide a
framework for understanding the molecular basis of epithelial
cell abnormalities in CF, help predict observed genotype–
phenotype correlations, and develop treatment approaches di-
rected to speciﬁc classes of mutations (e.g., Class I premature
stop mutations [24]). A comprehensive review of genotype–
phenotype relationships has recently been published (2).
CLINICAL PRESENTATION
Diagnosis
Although the genetic basis is now well understood, the diagnosis
of CF remains clinical and not genetic. Until the 1990s, the
diagnosis was based on clinical criteria (Table 1) and analysis
of sweat chloride values (25). The availability of mutational
analyses within the CF gene (12, 13) as well as an assessment
of bioelectrical properties of respiratory epithelia by measure-
ment of transepithelial potential differences (26) rapidly ex-
panded the clinical spectrum of CF to include milder, atypical
presentations. In addition, availabilityof newborn screening (27)
in certain states and countries and prenatal diagnosis afforded
the opportunity to diagnose individuals before the onset of clini-
cal symptoms. In 1997, a consensus panel was convened to deﬁne
the diagnosis of CF in the context of these newer diagnostic tools
(28). This group deﬁned the clinical parameters that support the
diagnosis(Table1)andappropriatelaboratoryteststodocument
CFTR dysfunction (28, 29). The World Health Organization has
developed similar criteria (30). Of the 1,091 newly diagnosed
patients from the United States in 2001 (6), only a small percent-
age were identiﬁed by newborn screening (9.1%) or prenatal
diagnosis (3.9%). The majority of diagnoses were based on clini-
cal features of which respiratory symptoms (43.8%), failure to
thrive (29.3%), steatorrhea (24.4%), and meconium ileus (18.5%)
were most common.
With these expanded criteria, the borders between normal
and abnormal CFTR function have become less distinct (29). A
particularly interesting group ismales with obstructive azoosper-
mia secondary to congenital bilateral absence of the vas deferens
whohavenootherclinicalfeaturesofCF.Nearlyhalftheindivid-
uals with congenital bilateral absence of the vas deferens carry
two CFTR mutations (31), and even patients with unilateral
absence of the vas deferens (32) have increased incidence of
CFTR mutations. Adults with chronic pancreatitis (33) and rhi-
nosinusitis (34) have been reported to commonly carry at least
one CFTR mutation. At the other end of the spectrum, CF
phenotypes have been characterized in the absence of CFTR
mutations (35). To address this conundrum, a continuum of
diagnoses from a pre-CF to subclinical CF to classic presentation
has been proposed (36). Thus, it is clear that the diagnostic
criteria will continue to evolve as molecular and physiologic
understanding expands.920 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 168 2003
Figure 2. The cystic fibrosis (CF)
transmembrane conductance
regulator (CFTR) gene and its
encoded polypeptide. The hu-
man CFTR gene (top) is located
on the long arm of chromo-
some 7 and consists of 27 exon
regions that encode the 1,480
aminoacidCFTRproteins(mid-
dle). The mature protein after
proper folding, glycosylation,
and insertion into the cell mem-
brane is shown at the bottom.
The CFTR protein is a member
of the ATP-binding cassette
(ABC) family of transporters. It
contains two nucleotide-bind-
ing domains that bind and hy-
drolyze ATP, two dual sets of
membrane-spanning segments
that form the channel, and a
central regulatory (R) domain.
The R domain, unique to CFTR,
is highly charged with numer-
ous phosphorylation sites for
protein kinases A or C. (Re-
printed by permission from
Reference 490.)
Figure 3. Functional effects of
classes of CFTR mutations. Five
classes of CF-related gene mu-
tations are displayed juxta-
posed to the normal matura-
tion pathway. As shown in the
left panel, wild-type CFTR is
transcribed into messenger
RNA (mRNA) followed by post-
translational modifications in-
cluding proper folding, glyco-
sylation, and trafficking via the
Golgi apparatus to the cell
membrane where it functions
as a regulated chloride chan-
nel. Class 1 mutations, exem-
plified by G542X, contain pre-
mature stop mutations that
create truncated mRNA. Class
2 mutations, of which F508 is
most common, are misfolded
andunabletoescapetheendo-
plasmic reticulum, where they
are ubiquitinated and de-
graded. Class 3 mutations, such
as G551D, reach the cell mem-
brane but the channel is not
properly activated. Class 4 mu-
tations, exemplified by R347P,
reach the cell surface and the
channel can be activated but have decreased chloride conductance. Class 5 mutations result in decreased abundance of CFTR, as exemplified by
incorrect splicing with the mutation 3849  10 kb C → T. With some Class 5 mutations a small percentage of correctly spliced mRNA are produced,
resulting in a milder phenotype. (Reprinted by permission from Reference 490.)State of the Art 921
TABLE 1. CLINICAL FEATURES CONSISTENT WITH THE
DIAGNOSIS OF CYSTIC FIBROSIS
Chronic Sinopulmonary Disease
Persistent colonization/infection with pathogens typical of CF lung
disease, including:
Staphylococcus aureus
Pseudomonas aeruginosa (mucoid and nonmucoid)
Nontypable Haemophilus influenzae
Burkholderia cepacia
Endobronchial disease manifested by:
Cough and sputum production
Wheeze and air trapping
Radiographic abnormalities
Evidence of obstruction on PFTs
Digital clubbing
Chronic sinus disease:
Nasal polyps
Radiographic changes
Gastrointestinal/nutritional abnormalities
Intestinal abnormalities:
Meconium ileus
Exocrine pancreatic insufficiency
DIOS
Rectal prolapse
Recurrent pancreatitis
Chronic hepatobiliary disease manifested by clinical and/or
laboratory evidence of:
Focal biliary cirrhosis
Multilobular cirrhosis
Failure to thrive (protein–calorie malnutrition)
Hypoproteinemia–edema
Fat-soluble vitamin deficiencies
Obstructive azoospermia in males
Salt-loss syndromes
Acute salt depletion
Chronic metabolic alkalosis
Definition of abbreviations:C F cystic fibrosis; DIOS  distal intestinal obstruc-
tion syndrome; PFTs  pulmonary function tests.
Adapted by permission from Reference 167.
Pulmonary Manifestations
CF primarily affects the airways and submucosal glands with
sparing of the interstitium and alveolar spaces until late in the
disease (Figure 4) (37). CFTR expression has been localized
to the affected regions with the most predominant expression
observed in submucosal glands (38). There are limited studies
Figure 4. Mucus plugging with airway inflammation. A slightly dilated
peripheralbronchusat lowpower,withsurroundingalveolar tissuefrom
a young adult with CF. The bronchus is filled with inflammatory cells
and mucus. The peribronchial region is also filled with inflammatory
cells (primarily neutrophils). By contrast, the parenchyma is spared both
inflammation and scarring.
Figure 5. End-stage bronchiectasis. A postmortem, pathology slide of
end-stage bronchiectasis in CF displaying dilated bronchi and mucus
impaction. The bronchiectatic airways contribute to reduced mucocili-
ary and cough clearance and the persistence of mucus inspissation and
endobronchialinflammation.Theparenchyma,evenwiththisadvanced
bronchial disease, is not severely altered.
describing thedevelopmental anatomy ofthe CF lungin affected
fetuses and newborns (39–41). The lungs, including mucus
glands, appear histologically normal at birth. There may be some
increase in the acinar diameter of the tracheal mucus glands,
suggesting some early mucus plugging preceding any evidence
of infection or inﬂammation (40).
Soon after birth, initial infection with bacterial pathogens
commences and is associated with an intense neutrophilic re-
sponse localized to the peribronchial and endobronchial spaces
(42–44). Early airway infection and inﬂammation in CF can
have regional heterogeneity that complicates understanding the
causal and temporal relationship between initial infection and
airway inﬂammatory response (45–47). Several studies in tod-
dlers and older children with CF have shown a robust inﬂamma-
tory response in the airways in both bacterial culture–positive
and culture-negative patients; some studies show a greater in-
ﬂammatory response in those patients with at least 5  104 cfu/ml
of bacteria in their bronchoalveolar lavage (BAL) ﬂuid (43,
48–50). At this point, pathologic changes become more evident
with mucopurulent plugging of small and medium size bronchi-
oles (Figure 4). In older individuals with CF, persistent neutro-
phils dominate airway inﬂammation with elevated interleukin
(IL)-8 and neutrophil elastase (51–53). Airways become dilated
and bronchiectatic, secondary to proteolysis and chondrolysis of
airway support tissue (54, 55) (Figure 5). In later stages, lung
parenchyma becomes affected by atelectasis, pneumonia, and
encroachment by enlarging airways. Many secondary conse-
quences of bronchiectasis ensue, including hypertrophy of bron-
chial circulation and formation of bronchial cysts. A later and
less common consequence is pulmonary hypertension.
In effect, the CF airway represents a prolonged primary in-
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CF host inﬂammatory response is unable to mature and promote
a macrophage-driven granulomatous response seen in other
chronic infections. It has been suggested that this inﬂammatory
response remains orchestrated by local airway epithelium–
pathogen interactions, rather than driven by T cells as part of
the systemic immune response (52).
The critical mediators for neutrophil inﬂux in the CF lung
include IL-8, tumor necrosis factor– and IL-1, complement-
derived chemoattractants, and leukotriene B4 (52, 56). IL-8, pro-
duced by stimulated epithelial cells, macrophages, and neutro-
phils, appears to be the predominant and sentinel neutrophil
chemoattractant in the CF airway (52, 57). IL-1, tumor necrosis
factor–, neutrophil elastase, LPS, and P. aeruginosa antigens
can all stimulate further IL-8 production to sustain the neutro-
philic inﬂux. Tumor necrosis factor– stimulates neutrophil se-
cretory and oxidative processes, and both tumor necrosis fac-
tor– and IL-1 can prime neutrophils for a heightened response
to chemoattractants. The activated neutrophils are the primary
effector cells for the pathogenesis of CF lung disease. Neutro-
phils release massive amounts of elastase and other proteases
that overwhelm the local host defenses including -1 antitrypsin
and secretory leukocyte protease inhibitor. As the neutrophils
breakdown,theyreleaselargeamountsofhighmolecularweight
DNA that increase the viscosity of the endobronchial secretions
that contribute to reduced mucociliary clearance (58).
The clinical manifestations of CF lung disease are highly
variable in onset and intensity. Affected individuals rarely dem-
onstraterespiratorysymptomsinthenewbornperiod,butinfants
less than6 months ofage may demonstratetachypnea, wheezing,
increased work of breathing, hyperinﬂation, and cough. These
symptoms may be initiated or exacerbated by respiratory viral
infections (59) and, if undiagnosed, these babies may be labeled
as having recurrent or persistent bronchiolitis. At some point in
the course of all affected individuals’ lives, cough becomes a
prominent symptom. Patients with mild disease may only cough
during exacerbations (see Treatment of Pulmonary Exacerba-
tion), but eventually cough becomes a daily occurrence, usually
associated with expectoration of sputum. With disease progres-
sion, daily sputum volume increases and becomes green to tan
in color. Blood-streaked sputum and hemoptysis are not unusual
in later stages of illness. Similar to other chronic obstructive lung
diseases, patients experience increasing dyspnea on exertion and
shortnessofbreathastheillnessprogresses.Theyareoftenoxygen
dependent (at least nocturnal) with retention of carbon dioxide
in the late stages of the illness and experience decreasing life
quality as the frequency of exacerbations and intensity of respira-
tory therapy increases. Respiratory failure still accounts for over
80% of deaths for patients with CF in the United States (6).
CFTR FUNCTION AND MOLECULAR BASIS OF
CF LUNG DISEASE
CFTR Structure and Function
CFTR is a member of the ATP-binding cassette transporter
family of membrane proteins (2, 60). CFTR contains the charac-
teristic two nucleotide-binding domains and two membrane-
spanning domains, as well as a unique regulatory R domain
withmultiplephosphorylationsites(Figure2).cAMP-dependent
phosphorylation of the R domain governs channel activity (61),
and ATP binding and hydrolysis by the two nuclear-binding
domains controls channel gating (62, 63). CFTR structure and
function, the regulatory activity of CFTR on other ion channels,
and the impact of CFTR dysfunction on the composition and
pH of ASL are reviewed elsewhere (2).
Impact of Defective CFTR on Airway Physiology and
Mucociliary Clearance
The net impact of aberrations in transepithelial ion ﬂow on the
ionic composition and volume of airway surface ﬂuid in CF due
Figure 6. Pathogenic events hypothesized to lead to chronic Pseudomo-
nas aeruginosa.( A) In normal airway epithelia, the presence of a low-
viscosity periciliary layer (PCL) of normal volume promotes efficient
mucociliary clearance. A normal rate of epithelial cell oxygen consump-
tion (QO2) results in no gradient in the partial pressure of oxygen (pO2)
within the airway surface liquid (ASL). In the CF airway, (B) isotonic
volume depletion of the PCL (denoted by downward arrows and bent
cilia) results in reduced mucociliary transport (bidirectional horizontal
arrow) and (C) persistent mucus hypersecretion (denoted by upward
arrows from secretory gland/goblet cell units) with time increases the
height of the luminal mucus layer/plugs. Elevated CF epithelial QO2
generates steep hypoxic gradients (dark color in pO2 bar) in the thick-
ened mucus layer. (D) P. aeruginosa bacteria deposited on mucus sur-
faces penetrate actively or passively (due to mucus turbulence) into
hypoxic zones of the mucus masses. P. aeruginosa adapt within the
hypoxic environment with increased alginate expression and the forma-
tionofmicrocolonieswithpotentialevolutionintobiofilms.(E)Increased
P. aeruginosa microcolony density and the presence of neutrophils ren-
der the mucus layer more hypoxic. P. aeruginosa microcolonies within
the hypoxic mucus plugs resist host lung defenses, including neutro-
phils, and result in chronic airway infection. (Adapted by permission
from Reference 97.)
to dysfunctional or absent CFTR is an active topic of investiga-
tion. ASL consists of two layers above the epithelial surface—a
mucus layer and a periciliary liquid layer with a height of the
extended cilium ( 7 m) (Figure 6A) (64). The periciliaryState of the Art 923
liquid layer volume is tightly regulated to provide a low-viscosity
solution for ciliary beat and to lubricate gel-forming mucins
secreted from the cell surface (64, 65). The mucus layer consists
of high molecular weight mucins whose properties are altered
by water content, ion concentrations, and pH. The diversity of
the carbohydrate side chains within the mucin gel is suited for
binding a wide variety of particles for ultimate clearance from
the airway (66).
Two competing hypotheses have been proposed: (1) the iso-
tonic “low volume” hypothesis with resultant abnormalities in
mucociliary clearance (64, 65), and (2) the “compositional” hy-
pothesis with increased ASL salt concentrations in CF inactivat-
ing salt-sensitive antimicrobial peptides (Figure 7) (67). Both
hypothesescaninpartexplaintheearlyandpersistentendobron-
chial infection in CF (68–70). In the ﬁrst hypothesis, water-
permeable airway epithelia regulate the volume of the ASL
by isotonic transport to maintain optimal ciliary mucus layer
interactions and mucociliary clearance. This hypothesis predicts
the salt composition of control and CF ASL to be similar with
each other and plasma. The second or “compositional” hypothe-
sis proposes that airway epithelia regulate ASL salt concentra-
tion that is critical for optimal function of innate antimicrobial
peptide defenses in the lung. This hypothesis predicts a higher
ASL salt concentration in patients with CF compared with indi-
viduals who are not infected.
There is no ﬁnal consensus on the tonicity of ASL in subjects
with CF relative to healthy control individuals. Technical limita-
tions of collecting and assaying ASL from the upper and lower
airways are a signiﬁcant obstacle. It is also uncertain if ASL
composition varies along the respiratory tract (i.e., nasal epithe-
lium to distal airways), in response to chronic inﬂammation and
infection, and within local microenvironments such as submuco-
sal glands or mucus plugs (68). There is increasing evidence from
nasal and bronchial epithelium derived from human and animal
sources that ASL is similar in healthy control individuals and
subjects with CF and is isotonic (64, 71–75). However, using a
novel isotopic technique, one investigator suggests that normal
ASL concentrations of sodium and chloride are approximately
50 mM and that the ASL concentrations of these ions are ele-
vatedto approximately100 mMin CF(76). Therefore,the “com-
positional” hypothesis has not been entirely refuted, especially
when considering local microenvironments such as submucosal
glands. Additional studies on the ionic composition and volume
of ASL are necessary, as the answer will inﬂuence approaches
to treatment of CF lung disease.
Evidence is accumulating for the important role of submuco-
sal glands in the pathophysiology of airway disease in CF (71).
CFTR is highly expressed in the serous epithelial cells of submu-
cosal glands compared with other tissues of the lung (38, 68).
Abnormalities in submucosal gland secretions are proposed to
contribute to airway disease in CF. Loss of CFTR function may
alter the macromolecular composition of the submucosal gland
secretions and thereby change viscosity, gel hydration, and ad-
versely effect mucociliary clearance (Figure 6D) (66, 71, 77).
Submucosal gland secretions from explanted human CF airways
have sodium content and pH similar to control tissue, but CF
submucosal gland secretions have approximately a twofold in-
crease in viscosity (77). Further studies are needed on submuco-
sal gland secretions from CF airways before chronic infection,
however, to determine if the increased viscosity of submucosal
gland secretions in CF is due to decreased ﬂuid secretion or
altered protein/glycoprotein composition.
Mucociliary clearance is a primary innate airway defense that
most studies show is reduced in CF (Figure 6) (64, 66, 78). In
CF, there is abnormal regulation of the periciliary liquid volume
that contributes to reduced mucociliary clearance (64, 66). Al-
tered viscosity and regulation of submucosal gland secretion
may also impair host defense (77, 79). In addition, the reduced
periciliary liquid volume promotes interactions between gel mu-
cins in the mucus layer with cell-surface mucins that hinder
clearanceofparticlesfromtheairways(66).Clearanceofparticles
from normal peripheral airways by mucociliary clearance can re-
quire up to 6 hours, and this can be signiﬁcantly prolonged in CF
airways (66). Endogenous antimicrobial peptides can suppress
bacterial growth for 3 to 6 hours (80). Thus reduced mucociliary
clearanceinCFmaycontributetooverwhelminginnateantimicro-
bial peptides and thereby promote the initial endobronchial infec-
tion in young children with CF.
Impact of Defective CFTR on Initial and Persistent
P. aeruginosa Infection
The abnormal composition and mechanical properties of airway
secretions does not explain the propensity for the CF airway
to become colonized with only a limited number of bacterial
pathogens,inparticular,P.aeruginosa.Thereareseveralhypoth-
eses to help us understand that association.
Abnormal bacterial adherence to epithelial cells. Initial infec-
tion may be related to increased P. aeruginosa adherence to
receptors in the CF airway (Figure 6C). CF epithelial cells dem-
onstrate greater adherence of piliated laboratory strains of P.
aeruginosa compared with control cells, and expression of wild-
type CFTR in CF cell lines results in reduced P. aeruginosa
binding(81–83).Thedegreeof P.aeruginosabindingwasgreater
in nasal scrapings from patients homozygous for F508 com-
pared with compound heterozygotes or carriers (84). The basis
for this increased adherence of piliated P. aeruginosa to the
apical surface of CF epithelial cells is proposed to be secondary
to increased asialoganglioside-1 (81, 82, 85). Asialoganglioside-1
receptors are increased in cells expressing mutant CFTR and in
areas of regenerating epithelium that are likely present in the
inﬂamed CF airway (82, 85). The mechanism by which mutations
in CFTR cause undersialylation of apical receptors is unknown
but proposed to be related to hyperacidiﬁcation of the trans-
Golgi network in CF epithelial cells (86). Proponents acknowl-
edge that asialoganglioside-1 is not a receptor for clinical mucoid
isolates without pili or ﬂagella (85), and therefore this host–
pathogen interaction may not be relevant to chronic P. aerugi-
nosainfection.Otherinvestigatorsrefutetheroleofasialogangli-
oside-1 as a signiﬁcant P. aeruginosa receptor in the CF airway
(87). Heparan sulfate proteoglygans on the basolateral surfaces
of epithelial cells are potential receptors for nonpiliated P. aeru-
ginosa in patients with chronic endobronchial infection and air-
way injury (88).
CFTR may serve as a receptor for P. aeruginosa internaliza-
tion.CFTRisproposedtobeareceptorforP.aeruginosabinding
to airway epithelium for subsequent phagocytosis and clearance
by desquamation (89–92). Therefore, reduced P. aeruginosa
binding to mutant CFTR results in reduced P. aeruginosa clear-
ance from the CF airway. It is postulated that this mechanism
is important in the initiation of endobronchial infection. The
complete LPS outer core is proposed to be the P. aeruginosa
ligand that binds to wild-type CFTR (90, 93). This hypothesis
is consistent with the observations that laboratory strains and
nonmucoid clinical isolates of P. aeruginosa, but not mucoid
isolates, bind to CFTR and are cleared more rapidly from wild-
type versus transgenic CF mice (94); overexpression of CFTR
in transgenic mice resulted in increased clearance of P. aerugi-
nosa from the lung (92). P. aeruginosa adaptation within the CF
airway is associated with modiﬁcations to LPS structure (95, 96);
the speciﬁc LPS structures required for P. aeruginosa binding
to CFTR have not been fully elucidated. There is no consensus
on the importance of this LPS–CFTR interaction in the patho-
genesis of CF lung disease.
The relative importance of epithelial cell phagocytosis in the
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mucociliary clearance and antimicrobial peptides. It is unlikely
that epithelial phagocytosis is important in established infection,
as mucoid P.aeruginosa and Staphylococcus aureusare observed
primarily within endobronchial mucus and not adherent to the
epithelium (97, 98).
Innate immunity and persistence of bacterial infections. Innate
immune responses provide the ﬁrst line of defense to airway
infection in concert with mucociliary clearance. Submucosal
glands, goblet cells of the large airways, Clara cells within the
small airways, and epithelial cells secrete proteins and peptides
into the ASL that can kill a broad spectrum of bacteria or
modulate the host inﬂammatory response (99, 100). Classic com-
ponents of the ASL with antimicrobial activity include lysozyme,
lactoferrin, secretory phospholipase A2, secretory leukocyte
protease inhibitor, and surfactant proteins (99, 100). Antimicro-
bial peptides of several classes, including - and -defensins and
cathelicidins,aresecretedfromcellularcomponentsoftheinnate
immunesystem.Someofthesepeptidesaresynthesizedconstitu-
tively (i.e., human -defensin 1), and others are upregulated in
response to inﬂammatory mediators, such as human -defensin
2 and LL-37 (2, 99–101). There is no evidence for a primary
defect in the production of these antimicrobial peptides residing
in the CF ASL. There have been reports, however, suggesting
that decreased concentrations of a circulating serum protein,
mannose-binding lectin, observed in individuals with polymor-
phisms in the mannose-binding lectin gene may contribute to
more rapid decline in pulmonary function and poor survival in
patients with CF colonized with P. aeruginosa and Burkholderia
cepacia (102, 103). This serum lectin, important in innate immu-
nity of both bacterial and viral infection, binds mannose and
N-acetylglucosamine oligosaccharides on the surface of microor-
ganismsactivatingthecomplementsystemandbindingreceptors
on phagocytes (104). A laboratory model has also demonstrated
that the mannose-binding lectin actively binds clinical strains of
B. cepacia, activating complement, but does not bind P. aerugi-
nosa isolates (105).
The central tenet of the “compositional” theory (see Impact
of Defective CFTR on Airway Physiology and Mucociliary
Clearance) is that the elevated sodium chloride content in CF
ASL (Figure 7) leads to inactivation of salt-sensitive antimicro-
bial peptides permitting initial bacterial colonization within the
CF airway (2, 67, 70). There are limited in vivo data to corrobo-
rate this theory (76). It has been postulated, however, that local
microenvironments such as mucus plaques or submucosal glands
in the CF airway, not easily reached for in vivo sampling, may
demonstrate conditions (salt content or binding to actin/DNA)
that can inactivate innate antimicrobial peptides to promote
initial bacterial infection (106). New data showing steep oxygen
gradients in mucus plagues within the CF airway has led propo-
nents of the “isotonic, low ASL volume” hypothesis to propose
a scheme for early and persistent endobronchial infection in CF
(97). In this model, the hyperabsorption of sodium and absent
chloride secretion in the CF airway result in reduced periciliary
liquid volume and impaired mucociliary clearance leading to a
cascade of events that provides a unique microenvironment to
promote P. aeruginosa adaption and persistent infection as illus-
trated in Figure 6.
Acquired immunity. There is no evidence for a systemic im-
munodeﬁciency in CF to explain the chronic endobronchial in-
fection. In CF, there is no increase in the frequency or severity
of infections outside of the respiratory tract and patients with
CF have normal immune responses to standard immunizations
(52). Patients with CF mount a signiﬁcant humoral response to
P. aeruginosa antigens, and there are emerging data that serum
antibodies directed against whole-cell P. aeruginosa lysates or
speciﬁc P. aeruginosa antigens can be the ﬁrst markers of P.
aeruginosa infection in young children with CF (107, 108). Pa-
tients with chronic P. aeruginosa infection demonstrate high
concentrations of antibodies directed against multiple P. aerugi-
nosa antigens. Despite this early and sustained immune response
to P. aeruginosa, the host is generally unable to clear P. aerugi-
nosa from the airways.
There are multiple factors, however, contributing to the inef-
fective acquired immune response (109). Opsonophagocytosis
of bacteria requires intact complement and Fc receptors on
phagocytes. In the CF airway, with neutrophil-dominated in-
ﬂammation, there is proteolytic cleavage of complement and Fc
receptors resulting in reduced opsonophagocytosis (52). Local
tissue destruction and reduced mucociliary clearance reduces
the effectiveness of the immune response in the clearance of
P. aeruginosa from the airway. Chronic P. aeruginosa antigen
exposure in patients with CF appears to result in a lack of avidity
maturation of anti–P. aeruginosa antibodies that may contribute
to reduced function in P. aeruginosa clearance (110).
All of the proinﬂammatory cytokines and chemokines ele-
vated in the CF airway have their synthesis regulated by the
transcription factor nuclear factor-B( N F - B) (52, 111). Con-
ﬂictingdataexistonthedegreeofNF-BactivationinCFepithe-
lia. Greater activation of NF-B has been observed in some
CF epithelial cell lines stimulated with P. aeruginosa or tumor
necrosis factor– compared with cells lines with wild-type CFTR
(83, 112). However, not all CF airway epithelial cell culture
modelsexhibitincreasedendogenousproinﬂammatorymediator
secretion (113). The etiology of increased NF-B activation in
some CF cell culture models appears to be multifactorial. First,
there is a proposed primary defect in the CF epithelium that
results in increased NF-B activation without external stimuli
(57, 114). Second, there are reduced IL-10 concentrations in
BAL ﬂuid from patients with CF and reduced production of
IL-10 from CF cell lines compared with control subjects (52).
IL-10 causes increased production of an inhibitor of NF-B
activation IB (52). In the setting of reduced IL-10 and IB
in the CF airway, there is unchecked NF-B activation. Other
investigators propose that a speciﬁc amino-terminus domain of
CFTR is a pattern-recognition molecule for the complete LPS
outer core, and binding of LPS to CFTR results in increased
NF-B activation (93).
MICROBIOLOGY OF CF LUNG DISEASE
CF has a unique set of bacterial pathogens that are frequently
acquired in an age-dependent sequence. The pattern of age-
speciﬁc prevalence as well as overall prevalence of these patho-
gens in the CF population in the United States is demonstrated
in Figure 8 from the Cystic Fibrosis Foundation Patient Registry
data (6). Of the organisms causing infection in CF, only S. aureus
may be pathogenic in immunocompetent individuals. P. aerugi-
nosa, B. cepacia, nontypeable Haemophilus inﬂuenzae, Stenotro-
phomonas maltophilia, and Achromobacter xylosoxidans are all
considered opportunistic pathogens. Other organisms seen in
CF that are also generally nonpathogenic in the healthy host
include Aspergillus and nontuberculous mycobacteria.
Early Colonization and Infection
Early infections in CF airways are most frequently caused by S.
aureus and H. inﬂuenzae, organisms that may be seen in other
young children with chronic illnesses and in adults with non–CF
bronchiectasis. S. aureus is often the ﬁrst organism cultured from
the respiratory tract of young children with CF (48). However,
there continues to be debate about the signiﬁcance of S. aureus
in the pathogenesis of CF lung infection (115). Historically, sig-
niﬁcant improvements in patient longevity have been associated
with the advent of antistaphylococcal therapy (116). However,State of the Art 925
Figure 7. Two hypotheses of how ASL differs in healthy and CF lungs.
(A) The low-volume hypothesis postulates that normal ASL (A1) has salt
levels approximately equal to plasma. In CF (A2), the removal of CFTRs
inhibition of epithelial sodium channels (EnaC) results in abnormally
elevated isotonic fluid absorption, which depletes the ASL and leads to
reduced mucociliary clearance. Key features of the low-volume model
are the parallel pathway for Cl	 via shunt pathway(s) and inhibition of
ENaC via CFTR. (B) The high-salt hypothesis postulates that normal ASL
has low levels of salt as a result of salt absorption in excess of water
(B1). Even though the epithelium is water permeable, salt is retained in
thin surface films by some combination of surface tension impermeant
osmolytes. In CF (B2), salt is poorly absorbed resulting in excessively salty
ASL that inactivates endogenous, salt-sensitive antimicrobial peptides.
Key features of the high-salt model are: the lack of an appreciable shunt
Cl	 conductance, central importance of CFTRs channel role, no specific
role for inhibition of ENaC by CFTR, and a switch from isotonic volume
absorption to hypertonic salt absorption as the surface layer thins and
traps residual water. (Reprinted by permission from Reference 70.)
several recently published studies of the efﬁcacy of prophylactic
antistaphylococcal antibiotics question the beneﬁt of this thera-
peutic approach (see Bronchodilators) (117, 118).
H. inﬂuenzae is also isolated from the respiratory tract early
in the course of CF. In a natural history study of CF diagnosed
in 40 children in the ﬁrst year of life, either for clinical reasons or
because of a family history, H. inﬂuenzae was the most common
organism isolated from lower airway cultures at age 1 year (50,
107). Similar numbers have been reported in studies of children
withCFidentiﬁedbyneonatalscreening(119).TheH.inﬂuenzae
Figure 8. Age-specific preva-
lence ofairway infectionsin pa-
tients with CF. Organisms re-
ported to the U.S. Cystic
Fibrosis Patient Registry, 2001.
Overall percentage of patients
(all ages) who had at least one
respiratory tract culture (spu-
tum, bronchoscopy, oropha-
ryngeal, or nasal) performed in
2001 that was positive for the
following organisms: Pseudo-
monas aeruginosa (red line),
58.7%; Staphylococcus aureus
(green line), 48.0%; Haemophi-
lus influenzae (dark blue line),
15.9%;Stenotrophomonasmal-
tophilia(yellowline),8.4%;Ach-
romobacter xylosoxidans (light
blue line), 4.4%; Burkholderia
cepacia (black line), 3.1%. (Re-
printed by permission from
Reference 6.)
infecting patients with CF is nontypeable, thus not prevented
by childhood immunization against H. inﬂuenzae type b. The
role of H. inﬂuenzae in progressive airway infection and inﬂam-
mation in patients with CF has not been clearly demonstrated,
although it is known to be pathogenic in patients with non–CF
bronchiectasis (120).
Infection with P. aeruginosa
P. aeruginosa is by far the most signiﬁcant pathogen in CF and,
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to occur much earlier than believed previously (107, 108, 119).
In a natural history study of patients with CF in the ﬁrst 3 years
of life, the mean age of detection of an antibody response to
P. aeruginosa was approximately 15 months, whereas the mean
agesofﬁrstpositiveupperandlowerairwayculturewereapprox-
imately 21 and 23 months, respectively (107). In a study of
68 patients with CF identiﬁed by neonatal screening, antibody
responses to P. aeruginosa were identiﬁed, on average, nearly
12 months before positive oropharyngeal (OP) cultures (lower
airway bacteriology was not available in these individuals) (108).
Risk factors for initial P. aeruginosa airway infection in patients
with CF diagnosed by newborn screening included female sex,
homozygous F508 genotype, and S. aureus isolation (121). Up
to 80% of patients with CF are eventually infected with this
organism (6), and acquisition of the organism is associated with
clinical deterioration (50, 122–124). The source of P. aeruginosa
isolates in patients with CF has not been clearly established.
There is a wide distribution of P. aeruginosa genotypes that
have been demonstrated in young children (107), suggesting
acquisition from environmental reservoirs, and only rarely do
patients with CF appear to share genotypes, generally only when
they are siblings or otherwise epidemiologically linked (125,
126). Comparison of genotypes from upper and lower airway
sources collected simultaneously from patients demonstrates
that distinct genetic strains may colonize different anatomic sites
in the CF airway (107, 127).
Characteristics of P. aeruginosa That Contribute to Initial
and Persistent Infections
InClinicalPresentationandCFTRFunctionandMolecular
Basis of CF Lung Disease, we have described unique character-
istics of the CF airway that enhance the propensity for P. aerugi-
nosa to initially colonize. Given this opportunity, the pathogens’
own genetic and phenotypic plasticity enables adaptation to es-
tablish a persistent infection.
Phenotypic changes. P. aeruginosa isolates from the lungs of
patients with CF are quite distinctive from those causing acute
infection in other settings. These characteristics are not present
in isolates causing initial colonization but appear to be selected
within CF airways and occur increasingly with length of lung
infection. Whereas early isolates appear much like environmen-
tal isolates in their phenotype, later isolates are more resistant to
antibiotics and frequently mucoid (107). Additional phenotypic
changes seen in CF isolates of P. aeruginosa include the loss of
O-side chains on LPS making the strains nonreactive with typing
sera (128), distinctive acylation of LPS (96), loss of ﬂagella-
dependent motility (129), and increased auxotrophy (130).
Although growth of P. aeruginosa in microcolonies has been
proposed for many years (131), support for the existence of
bioﬁlms in CF has recently been reported (132, 133). Bioﬁlms
are sessile communities of bacteria that form in aggregates on
surfacesusingahydratedpolymericmatrixoftheirownsynthesis
(Figures 6D and 6E). Some common clinical characteristics of
bioﬁlm infections have been identiﬁed: slow growth of organ-
isms, stimulation of production of antibodies that are ineffective
in clearing bacteria, inherent resistance to antibiotics, and an
inability to eradicate bioﬁlm infections even in hosts with intact
immunesystems(134–137).ThesearecharacteristicofCFairway
infections.
The presence of P. aeruginosa bioﬁlms in infected CF airways
was ﬁrst suggested because of the quorum-sensing signals that
the organisms produce to signal cell-density–dependent gene
expression (132). In addition, both transmission and scanning
electron microscopy have demonstrated organized clusters and
microcolonies of P. aeruginosa in expectorated CF sputum con-
sistant with bioﬁlm formation (138). Subsequently, the presence
of local hypoxia within mucus plaques in the airways has been
suggested to increase Pseudomonas alginate production (97),
which may lead to increased bioﬁlm formation (Figure 6) (138).
It has recently been reported that antibiotic-resistant phenotype
variants of P. aeruginosa with an enhanced ability to form bioﬁlms
arise at high frequency in the lungs of patients with CF (133).
Genetic advantages. The knowledge gained from the recently
available genome sequence of a laboratory strain of P. aerugi-
nosa, PAO1, helps explain much of the phenotypic diversity of
the organism (139). P. aeruginosa has a very large genome—at
6.3Mbpitis37%largerthanthebest-studiedbacterialpathogen,
Escherichia coli, which has a genome size of 4.6 Mbp. With 5,570
predicted open reading frames, the genetic complexity of P.
aeruginosa approaches that of the simple eukaryotic organism,
Saccharomyces cereviseae. This complete genome offers the po-
tential for a tremendous ability to adapt to multiple different
environments, including the CF airway. P. aeruginosa isolated
from CF sputa have even larger genomes than the laboratory
strain, PAO1, suggesting that they have acquired new genes
duringtheiradaptation,inadditiontoalterationsinthosealready
present (140).
A high frequency of hypermutability has been identiﬁed in
P.aeruginosa isolatesfrom patientswithCF. Thisis likelycaused
by the milieu of the CF airway with large numbers of infecting
organisms and compartmentalization of infection, combined
with ineffective host defenses and ongoing antibiotic selective
pressure (141).
Late-emerging Pathogens
Other organisms that are identiﬁed later in the course of CF
airways disease include B. cepacia, S. maltophilia, A. xylosoxi-
dans, fungi including Aspergillus, and nontuberculous mycobac-
teria. Of these, B. cepacia is the most serious because of its
association with the B. cepacia syndrome leading to high fevers,
bacteremia, rapid progression to severe necrotizing pneumonia
and death. The majority of infected patients have a more chronic
course with decline in lung function and increased mortality
(142, 143). However, recent studies have demonstrated that
B. cepacia is not a single species but rather a group of closely
relatedspecies,termed“genomovars;”thus,theorganismshould
be called B. cepacia complex. At least nine distinctive genomo-
vars of B. cepacia have been identiﬁed and several have been
named as distinct species (144, 145). The vast majority of CF
airwayinfectionswithB.cepaciacomplexarecausedbygenomo-
vars II (Burkholderia multivorans), III (Burkholderia cenocepa-
cia)a n dV( Burkholderia vietnamiensis) (146). Although there
are exceptions, most of the severe infections and strains that
have been spread in epidemics are from genomovar III (147).
Several clonal lineages are distributed widely across Europe
and North America (146–148). In general, infection with other
genomovars is associated with less severe disease.
S. maltophilia and A. xylosoxidans are seen more commonly
than B. cepacia in patients with CF with advanced lung disease
but are generally less virulent. Epidemiologic studies examining
their association with morbidity and mortality in CF have not
demonstrateda correlationbetween infectionand outcome(149,
150).LikeP.aeruginosa,person-to-personspreadoftheseorgan-
ismsisrarely documentedinpatientswithCF, otherthansiblings
(151).
Fungal colonization and infection of the CF airway late in
disease progression is not surprising given the exposure of this
population to frequent broad-spectrum antibiotic therapy (152).
Whereas Candida spp. are the most frequent colonizers, isolated
from almost 50 to 75% of patients with CF who were cultured
(153, 154), they are usually considered to be harmless commen-
sals.However,Aspergillusspp.,mostfrequentlyAspergillusfum-State of the Art 927
igatus, are isolated from more than 25% of patients (154). There
is not sufﬁcient evidence to generally recommend treatment of
an Aspergillus-postive sputum culture in the absence of allergic
bronchopulmonary aspergillosis (ABPA) (155). Invasive infec-
tions caused by Aspergillus are rare in the immunocompetent
nontransplant CF population, but ABPA can be a signiﬁcant
problem (156, 157).
ABPA is not an invasive fungal infection but rather a syn-
drome, including wheezing, pulmonary inﬁltrates and, poten-
tially, bronchiectasis and ﬁbrosis, that develops because of sensi-
tization against allergens from A. fumigatus in the environment
(156, 157). Exposure of the airways to high levels of Aspergillus
allergens, due in part to reduced mucociliary clearance in CF,
may be a key element in the development of ABPA. In patients
with atopy, exposure to fungal spores and hyphal elements leads
to the production of speciﬁc IgE and an increase in the CD4
Th2 cell response to A. fumigatus (157). The overall prevalence
of ABPA in CF is reported between 2 and 8% on the basis of
three large clinical databases (157–159). The true prevalence of
ABPA in the CF population is uncertain due to the lack of
standardized diagnostic criteria and the lack of uniform surveil-
lance and laboratory procedures (see Diagnosis and Treatment
of ABPA).
Another ﬁlamentous fungus isolated commonly from the re-
spiratorytractofpatientswithCF(8.6%ofpatientsinonestudy)
whose signiﬁcance is unknown is Scedosporium apiospermum
(160). For both Aspergillus and Scedosporium, no clustering of
isolates has been identiﬁed by genotyping (161, 162). Other
molds that have been reported from CF respiratory samples in-
clude Wangiella dermatitidis and Penicillium emersonii (163, 164).
Nontuberculous mycobacteria have been increasingly re-
ported from the respiratory secretions of patients with CF. In a
prospective prevalence study conducted at 21 CF centers across
the United States, 13% of patients cultured nontuberculous
mycobacteria from sputum (165). The most common species iso-
lated were Mycobacterium avium complex (72%) and Mycobac-
terium abscessus (16%). Nontuberculous mycobacteria culture-
positive patients were more frequently older and had a higher
frequency of S. aureus and a lower frequency of P. aeruginosa
compared with culture-negative control subjects. Molecular typ-
ing demonstrated a pattern of infrequent spread among patients.
Thereappeared,however,tobeadistinctgeographicdistribution
of the prevalence of nontuberculous mycobacteria. Prevalence
ranged from 7% in Boston to 24% in New Orleans, and the
majority of centers with a rate greater than 15% were in coastal
states.
A substudy that followed 60 nontuberculous mycobacteria–
positive patients for 15 months and compared them with an
uninfected control group identiﬁed no difference in the rate of
decline of FEV1 (166). Abnormalities on high-resolution compu-
terized tomography (HRCT) scan, however, were predictive of
progression. Thus, current recommendations suggest that adult
patients with CF be screened on a regular basis with both acid-
fast smear and appropriately processed sputum or BAL ﬂuid
culture (see Nontuberculous Mycobacteria). Findings sug-
gestive of infection rather than colonization include: multiple
positive cultures, a single positive culture associated with a pul-
monary exacerbation that is not responsive to conventional
antibacterial therapy or HRCT scan demonstrating peripheral
pulmonary nodules, and/or a mucosal biopsy demonstrating granu-
lomatous disease.
CLINICAL ASSESSMENT IN THE MANAGEMENT
OF CF LUNG DISEASE
Monitoring Pulmonary Health Status
There is no approved therapy to correct the underlying genetic
defect or reverse the ion transport abnormalities associated with
dysfunctional CFTR. Thus, therapy is directed toward slowing
the progression of secondary organ dysfunction and its sequelae
such as pancreatic insufﬁciency with maldigestion and chronic
endobronchial infection. This treatment approach has been en-
hancedbytheestablishmentofcomprehensive,multidisciplinary
CF care centers worldwide. The Cystic Fibrosis Foundation has
also established Clinical Practice Guidelines (167) followed by
CF centers throughout the United States emphasizing routine
quarterly monitoring of health status, patient and family educa-
tion, and early intervention to slow illness progression (2).
Routine laboratory evaluations are key to assessing pulmo-
nary status and are used to monitor disease progression and
response to therapeutic interventions. These studies include ra-
diologic examinations, pulmonary function testing, and microbi-
ologic cultures of airway secretions. Assessment of blood oxygen
andcarbondioxidevaluesareusefulinpatientswithmoresevere
disease or acute pulmonary decompensation. Management of
endstage lung disease including intensive care management–
assisted ventilation and transplantation is beyond the scope of
this review and has been reviewed (168–173).
Imaging. Chest X-rays are most helpful for deﬁning disease
progression and less sensitive in demonstrating changes during
acute pulmonary exacerbations or early, mild disease. Hyperin-
ﬂation with ﬂattened diaphragms and retrosternal lucency may
occur in early infancy and remain a prominent ﬁnding through-
out the life of the patient. Progressive ﬁndings include nodular
opacities due to mucus plugging and cystic changes due to bron-
chiectasis. Chest X-ray scores (174–176) have been developed
for assessing disease progression but have never been widely
used for routine patient management.
HRCT is more sensitive and speciﬁc than chest radiographs
in identifying changes such as airway wall thickening and gas
trapping in early CF lung disease and is particularly useful in
identifying localized areas of bronchiectasis and parenchymal
abnormalities (177–179). HRCT changes may also precede
changes in pulmonary function, which assess an overall change
in function rather than regional changes in structure (46, 180).
For these reasons, HRCT is being used to document early bron-
chiectasis, localized disease, and response to antibiotic interven-
tions during acute exacerbations (178, 181). Despite this prog-
ress, there are still no consensus guidelines for use of HRCT in
CF care; the risk versus beneﬁt ratio must continue to be ad-
dressed in terms of additional cost and radiation exposure (182).
Lung function testing. The principal measure of pulmonary
status in individuals with CF older than 5 years of age is pulmo-
nary function testing with spirometry or plethysmography. Serial
measurements document stability or progression of airway ob-
struction and air trapping. Lung function measurements are also
useful in documenting acute changes associated with pulmonary
exacerbations and response to therapy. Most children are able
to perform reproducible spirometric maneuvers according to
American Thoracic Society guidelines (183) by age 5 to 6 years.
In young children and older patients with minimal pulmonary
involvement, values for FVC, FEV1 and mean forced expiratory
ﬂowduringthemiddlehalfoftheFVC(FEF25–75%)maybenormal
when compared with reference values from healthy, sex, age,
and height-matched individuals (6). The earliest spirometric evi-
dence of obstructivedisease (presumably due tomucus plugging,
airway edema, inﬂammation, and increased secretions) is a de-
crease in expiratory ﬂows at low volumes such as FEF25–75% al-
though these changes are highly variable (184, 185). Another
early ﬁnding may be elevated residual volume (RV) and an
increasedratioofRVtototallungcapacity(RV/totallungcapac-
ity) consistent with gas trapping. This measurement should be
determined by plethysmography as total lung capacity may be
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Changes in FEV1 will become evident as patients begin to
develop obstructive lung disease. FEV1 is the most widely used
pulmonary function testing parameter of lung status (186–188)
in CF because of the universal accessibility of spirometric equip-
ment,standardizedcriteriaforperformance,availabilityofrefer-
ence values (189–191), and reproducibility. In addition to day-
to-day clinical management, FEV1 serves two other important
functions. First, it is the primary marker for disease progression
identiﬁed in numerous epidemiologic studies to predict survivor-
ship and decline in health status (122, 188, 192–195). Second, it
istheprimaryoutcomemeasureusedfordeﬁningclinicalefﬁcacy
for new therapeutic modalities in CF (187, 196, 197).
Across the entire U.S. CF population, the average decline in
FEV1is 2%per annum (186). Factors that maynegatively impact
the rate of decline include nutritional status (198), comorbidity
fromdiabetesmellitus(199,200),colonizationwithP.aeruginosa
(122, 124), and B. cepacia (142, 143) and frequency of pulmonary
exacerbations (122). Other factors such as mild genotype and
pancreatic sufﬁciency are associated with slower rates of decline
(122, 201). Patients may be stable for many years and then show
periodsofmorerapidprogression.AsFEV1continuestodecline,
patients will begin demonstrating a decline in FVC presumably
due to progressive scarring, gas trapping, and increased dead
space ventilation.
Infant pulmonary function testing. There is no simple, sensi-
tive, reproducible measure of lung function in children less than
6 years of age. Techniques used for testing pulmonary function
in children less than 3 years of age (202) require sedation and
are only performed in specialized centers. The most promising
technique developed in recent years is to raise the lung volume
of infants to near total lung capacity before performing a rapid
thoracic compression (203–208), yielding measurements that
closely approximate the voluntary spirometric maneuvers of
older children and adults. These measurements, more likely to
be effort-independent and reﬂect underlying lung mechanics,
demonstrate improved sensitivity (204, 208, 209), and decreased
measurementvariability(203,210).Referencedataforlungfunc-
tion in normal control subjects using these new measures are
now published (206, 207).
Current methods of infant lung function testing cannot be
extended beyond 3 to 4 years of age because of the inability to
provide adequate oral sedation and loss of the Hering–Breuer
reﬂex (relaxation of inspiratory muscles with repeated sigh
breaths). Promising measures of lung function in preschool pa-
tients with CF (ages 3–6 years) that can be performed without
sedation and during tidal breathing are being developed. These
techniques include modiﬁed spirometry (211, 212) and respira-
tory resistance measured by plethysmography (202, 213), forced
oscillation (214, 215), and interrupter resistance (216).
Diagnostic Microbiology
Culture of respiratory tract specimens from patients with CF
can present challenges to microbiology laboratories unaccus-
tomed to processing CF samples. Issues include nonrepresenta-
tive sampling of inhomogeneous specimens and polymicrobial
infections.Inaddition,manyoftheavailablecommercialsystems
for organism identiﬁcation and antimicrobial susceptibility test-
ing are inaccurate for CF pathogens (217–220).
Source of specimens. Expectorated sputum is an accurate
indicator of lower airway microbiology (127, 221, 222) and the
preferred source of airway secretions for management of CF
lung diseases. However, sampling may be difﬁcult in the younger
patients and in patients with mild disease who do not expecto-
rate. Two options that have been well studied are OP cultures
and cultures collected by BAL. Several studies have compared
these two measures of airway infection in CF (119, 127, 223,
224). One review that combined data from three prospective
clinical studies (223) using simultaneous OP and BAL cultures
(from 141 infants) found that the sensitivity of OP cultures in
predicting lower airway P. aeruginosa was poor (44%; 95% con-
ﬁdence interval, 14–79%) but that the speciﬁcity was good (95%;
90–99%). These ﬁndings suggest that a negative OP culture is
useful in ruling out lower airway infection, but that a positive
culture is not reliable to make the diagnosis of P. aeruginosa in
the lower airway. Culture of BAL ﬂuid is considered a more
sensitive measure of infection in nonexpectorating patients but
the procedure is more invasive and requires sedation, thus in-
creasing the risk and the cost. In addition, BAL is usually per-
formed in just one lobe, which increases the risk of missing
regional disease (45, 47). For these reasons, clincians generally
use OP cultures as their initial source of microbiology specimens
andreserveBALforpatientsunresponsivetoantimicrobialther-
apy or those with progressive disease.
Recently, hypertonic saline induction of sputum has been
reported to be a good surrogate for lower airway sampling for
both microbiology and inﬂammatory markers in both adult and
older pediatric patients with CF (222, 225–227). In a comparison
ofcultureresultsfromexpectoratedandinducedsputumsamples
and BAL ﬂuid, similar detection rates for bacteria and fungi
were identiﬁed with all three sample sources (222).
Isolation/identiﬁcation techniques. Isolationand identiﬁcation
of bacterial pathogens from CF respiratory secretions is not
straightforward for several reasons. Both expectorated and in-
duced sputum samples are frequently very viscous requiring
special processing to adequately sample the entire specimen. In
addition, most CF airway infections are polymicrobial, and the
organisms present may have very different growth requirements.
P. aeruginosa is often present and, because of its mucoid pheno-
type, frequently overgrows both Gram-positive organisms such
as S. aureus, and more fastidious or slower-growing Gram-nega-
tive organisms such as H. inﬂuenzae and B. cepacia. The use of
selective media that inhibit the growth of P. aeruginosa is very
helpful for the isolation of S. aureus and H. inﬂuenzae and
is mandatory for the isolation of B. cepacia (Table 2) (153,
228–230).
Once organisms are isolated, identiﬁcation, particularly of
Gram-negative bacteria, may also be difﬁcult because of the
presence of a large number of unique organisms combined with
the phenotypic changes that even the more common organisms
may undergo. The use of standard biochemical testing rather
than commercial systems has been recommended for identiﬁca-
tion of Gram-negative nonfermenting bacteria (217, 218). In
addition, molecular techniques, especially polymerase chain re-
action, have proved useful for bacterial identiﬁcation, both di-
rectly in sputum and for isolated organisms growing in pure
culture (231–233).
Antibiotic susceptibility testing. Susceptibility testing of CF
isolates is also potentially difﬁcult, for many of the same reasons
that affect organism isolation and identiﬁcation. Slow growth
and mucoidy may impact the utility of automated systems for
susceptibility testing of P. aeruginosa as well as for organism
identiﬁcation (219, 220). When compared with broth microdilu-
tion methodology, agar diffusion methodologies including disk
diffusion and E-test performed well for the majority of antibiot-
ics tested (234).
Whereas clinicallaboratories have not beenroutinely looking
for methicillin resistance in S. aureus isolated from patients with
CF, a survey of isolates from multiple CF centers suggested that
the rate of resistancein CF is comparable with thatin the general
population (153). Vancomycin tolerance and resistance have
both been described in human isolates of S. aureus (235–237),
and there is no reason to believe that patients with CF will be
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TABLE 2. RECOMMENDED SELECTIVE MEDIA AND CULTURE CONDITIONS FOR ISOLATION OF
CYSTIC FIBROSIS PATHOGENS FROM RESPIRATORY SAMPLES
Bacteria Recommended Media and Conditions*
Staphylococcus aureus Mannitol salt agar
Columbia/colistin–nalidixic acid agar
Haemophilus influenzae Horsebloodorchocolate agar(supplementedornotwith300g/mlbacitracin);incubated
anaerobically
Pseudomonas aeruginosa MacConkey agar
Burkholderia cepacia complex† BCSA
OFPBL agar
PC agar
Stenotrophomonas maltophilia MacConkey agar
VIA agar‡
DNase agar used for confirmation§
Achromobacter xylosoxidans MacConkey agar
Definition of abbreviations: BCSA  B. cepacia selective agar; OFPBL  oxidative-fermentative polymyxin B, bacitracin, and
lactose; PC  Pseudomonas cepacia; VIA  vancomycin-imipenem-amphotericin.
* Media listed are commercially available.
† Detection of B. cepacia complex may be enhanced by prolonging incubation for as long as 4 days to allow slow-growing
colonies to become apparent.
‡ Mannitol agar base media containing vancomycin–imipenem–amphotericin B as selective agents.
§ Agar containing DNA with toluidine blue as an indicator of deoxyribonuclease activity.
Other nonstandard methods for susceptibility testing in CF
include synergy testing of multiply-resistant Gram-negative iso-
lates and multiple combination bactericidal testing of P. aerugi-
nosa and B. cepacia complex (238). Ongoing trials of the clinical
utility of multiple combination bactericidal testing testing for
the management of B. cepacia complex lung infections are being
conducted in Canada. More recently, evidence of bioﬁlm forma-
tion by organisms in the CF airway has prompted the investiga-
tion of bioﬁlm susceptibility testing (239). Different drugs and
drug combinations appear to be efﬁcacious against P. aeruginosa
growing in bioﬁlms; this may help explain nonbactericidal mech-
anisms of activity of antimicrobial therapy. At this time, many
of these nonstandard techniques cannot be recommended for
routine use in CF because their clinical efﬁcacy has yet to be
tested.
Pseudomonas serology. The serologic diagnosis of P. aerugi-
nosa infection in CF has been used clinically in Europe for many
years (109, 110, 240–244) and as a research tool in the United
States and Canada (107, 108, 245, 246). In early respiratory tract
infection with P. aeruginosa, serology may be more sensitive
than OP culture (108). Although in patients with established
infection P. aeruginosa antibody levels rarely decrease in re-
sponse to antimicrobial therapy (247), low titers in response to
treatment with inhaled tobramycin have been documented in
patients with early P. aeruginosa colonization (248). Despite
the utility of serologic evaluation, it is considered primarily a
research tool in the United States because commercial tests
are not widely available. Techniques with promise include both
ELISA and Western blot.
Nontuberculous mycobacteria. Mycobacteria are very slow
growing organisms and require supplemented media to grow.
Thus, without inhibition of the P. aeruginosa and other less
fastidious organisms within CF specimens, they are frequently
overgrown. This technique was used to examine 986 sputum
specimens from patients at 21 CF centers in the United States,
identifying a 13% infection rate (165). This methodology uses
0.25%N-acetyl-l-cysteineand1%sodiumhydroxidedecontami-
nationfollowed by5% oxalicacid treatment(249).The optimum
processing of CF samples for nontuberculous mycobacteria has
been reported and resulted in P. aeruginosa contamination of
only 3 to 5% of the specimens (249).
CURRENT ANTIBIOTIC THERAPIES
Appropriate antibiotic therapy directed against bacterial patho-
gensisolatedfromtherespiratory tractisanessentialcomponent
in the management of CF lung disease. Most clinicians prescribe
antibiotic therapies in three distinct clinical settings during the
lifespan of an individual with CF. First, during early lung disease
patients may receive antibiotics to delay onset of chronic coloni-
zation with P. aeruginosa. Second, once patients are colonized
with pathogens such as S. aureus and P. aeruginosa, chronic
maintenance antibiotics are administered to slow decline in pul-
monary function and reduce frequency and morbidity of pulmo-
nary exacerbations. Third, at the time of periodic exacerbations
in pulmonary symptoms, intensive antibiotic regimens are fre-
quently administered during hospitalization to relieve symptom-
atology and restore pulmonary function to baseline values. The
current recommendations for antibiotic therapy in each of these
settingsandthebodyofscientiﬁcknowledgeonwhichtherecom-
mendations are based are outlined below. Two basic principles
shouldbeconsideredforallantibioticchoicesinCF.First,antibi-
otic selection should be based on periodic isolation and identiﬁ-
cationofpathogensfromrespiratorysecretionsandreviewofthe
antimicrobial susceptibility proﬁle for those pathogens. Second,
indiscriminant use of antibiotics without thoughtful considera-
tions of the rationale, clinical endpoint, and duration should be
avoided.
Prevention of Chronic P. aeruginosa Infection
Characteristics of P. aeruginosa isolates initially infecting the CF
airway appear more favorable for eradication with appropriate
antibiotic therapy. They are usually nonmucoid, highly suscepti-
ble to antibiotics, and present in lower density than established
infections (50, 107, 123).Thus, early aggressive antipseudomonal
antibiotic therapy has been advocated to delay onset of chronic
P.aeruginosainfection (250)onthebasisof ﬁndingsfromseveral
studies of eradication and delayed reinfection with this pathogen
(248, 251, 252). Although encouraging, interpretation of these
study results has been hampered by small sample sizes, lack of
control subjects or use of historic control subjects, and different
study endpoints. Despite the poor predictive value of upper
airway cultures (see Source of Specimens), only two studies
(123, 246), one controlled and one uncontrolled, have examined
the impact of early antipseudomonal therapy on lower airway
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eradication of P. aeruginosa in all 8 patients who received 28
days administration of inhaled tobramycin (300 mg twice daily)
and only 1 of 13 receiving placebo. The study was stopped by
the Data Safety Monitoring Board after completion of only 25%
of the proposed enrollment because of the signiﬁcant microbio-
logic treatment effect. Although these ﬁndings are encouraging,
the second study (123) reported persistent eradication of P.
aeruginosainthelowerairwayinonly25%ofsubjects,12months
posttherapy.
Duration of eradication is variable and likely depends on
patient selection criteria, source of respiratory secretions (upper
vs. lower airway) and duration and type of therapy. This issue
wasrecentlyaddressedinastudythatfollowedquarterlycultures
and P. aeruginosaserology on 19 childrenafter antipseudomonal
treatment of their ﬁrst P. aeruginosa–positive OP cultures (253).
Themeandurationoferadicationwas8months,andthemajority
of patients became infected with a new, genetically distinct P.
aeruginosa. A second study reported a longer upper airway
pathogen-free period after 12 months of inhaled antibiotics
(248). It is likely that without ongoing antibiotic suppression,
reinfectionwilloccur.Thesafetyoflong-termantibioticsinthese
young patients and the impact on airway microbial ﬂora is not
known. Although accumulating data suggest that early antibiotic
therapy results in P. aeruginosa eradication from both the upper
and lower airway, there are no controlled trials providing com-
pelling evidence of clinical beneﬁt in this population. There is a
critical need therefore for a large, adequately powered, placebo-
controlled clinical trial to address the clinical efﬁcacy and safety
of antipseudomonal therapy in this early infected population.
Maintenance Therapy
Antistaphylococcal antibiotics. Continuous antistaphylococcal
antibiotic usage in CF was a common practice in the latter half
of the 20th century and was believed to contribute to decrease
mortality in young patients (116, 254). In recent years, both
randomized clinical trials (118, 255, 256) and retrospective data-
base reviews (117, 257) have questioned the validity of this ap-
proach.Inasmallstudy,42infantsdiagnosedbynewbornscreen-
ing (255) were randomized to receive either continuous oral
ﬂucloxacillin or episodic antibiotics as clinically indicated for the
ﬁrst 24 months of life. Treated patients had fewer isolates of S.
aureus, less cough, and shorter hospital stays, but there was no
difference between groups in terms of lung mechanics. A large
multicenter,randomized,placebo-controlledtrialof209children
(mean age 15 months), 119 of whom completed a 5-year course
ofeither continuouscephalexinor placebowas recentlyreported
(118). Subjects who received cephalexin were less likely to be
culture positive for S. aureus but more likely to be culture posi-
tive for P. aeruginosa. There were no differences between the
groups in any clinical outcome measures including pulmonary
function, weight gain, or chest radiograph score. A large retro-
spectivedatabasereview(117)ofpediatricpatientsnotcolonized
with P. aeruginosa demonstrated no differences in clinical out-
comes between patients treated with continuous versus intermit-
tent antistaphylococcal antibiotics. Continuously treated pa-
tients again, had lower prevalence of S. aureus but signiﬁcantly
higher rates of P. aeruginosa acquisition. From these accumulat-
ing data, use of continuous antistaphylococcal antibiotics is no
longer recommended as there is no clear evidence of clinical
beneﬁt and may select for P. aeruginosa in the airway. Intermit-
tent antistaphylococcal treatment for respiratory symptoms is
appropriate.Appropriateantistaphylococcalantibioticsanddos-
age ranges are provided in both Tables 3 and 4.
An additional concern for indiscriminant use of antistaphylo-
coccal antibiotics is the emergence of methicillin-resistant S.
aureus strains in this population. Whether this concerning trend
is due to antibiotic usage in CF or the dramatic worldwide in-
crease in prevalence (258, 259) is not known. All S. aureus iso-
lates should be tested for methicillin resistance. The treatment
of choice for methicillin-resistant S. aureus is vancomycin; alter-
native therapies include clindamycin, trimethoprim/sulfameth-
oxazole, and quinolones for individuals who do not tolerate
vancomycin, if susceptibility testing indicates their activity (Ta-
bles 3 and 4). Some methicillin-resistant S. aureus strains now
demonstrate resistence to glycopeptides such as vancomycin
(236, 260), and in this setting an oxazolidinone such as linezolid
(261) may be effective.
The ﬁnding of slow growing isolates of both S. aureus and
P. aeruginosa, called “small colony variants” in respiratory tract
cultures from individuals with CF has also impacted antimicro-
bial therapy. These variants likely arise from antibiotic pressure
combined with unique CF airway milieu (262–264). These cell
wall–deﬁcient phenotypic variants have the ability to survive
intracellularly in neutrophils evading host defenses. In addition,
someclassesofantibioticsarelessactiveincluding,theaminogly-
cosides, antifolate antibiotics such as trimethoprim/sulfamethox-
azole, and cell wall–active agents such as the -lactams (263,
265). Therefore, alternative nonaminoglycoside, noncell active
classes of antibiotics should be considered, in consultation with
experts in microbiology. Clinical data demonstrating the role of
the small colony variants in disease progression is lacking, and
the value of antibiotic treatment is not known.
Antipseudomonal antibiotics. Maintenance therapy for pa-
tients colonized with P. aeruginosa has ranged from quarterly
intravenous antipseudomonal antibiotics (266) to inhaled antibi-
otics to oral quinolones or macrolides. Although many of these
therapies are empiric, recent large, randomized, placebo-con-
trolled trials have documented that maintenance antibiotic ther-
apy in patients chronically colonized with P. aeruginosa can
stabilize pulmonary function and decrease morbidity (197, 267).
Inhaled antibiotics, in particular aminoglycosides, have at-
tractedinterestformanyyearsbecauseofthegreatertherapeutic
index achieved by direct delivery of high-dose antibiotics to
the endobronchial space with limited systemic absorption and
toxicity(268).Inaddition,aerosoladministrationofhighconcen-
trations of aminoglycosides overcomes the antagonistic effects
of purulent CF airway secretions on aminoglycoside bioactivity
(269, 270). Early studies of both low-dose (60–80 mg thrice daily)
(271) and high-dose (600 mg thrice daily) (272) inhaled amino-
glycosides were encouraging and demonstrated improved lung
function and/or decreased hospitalization rate. Subsequently, a
large Phase III, placebo-controlled study of 300 mg of inhaled
tobramycin administered twice daily (cycling 28 days on, 28 days
off therapy) for 6 months reported a 10% relative increase in
FEV1 and 36% reduction in use of intravenous antibiotics in the
treatment group as compared with the placebo group (197).
There waslimited systemic absorptionand no oto-or nephrotox-
icity detected. In 2001, 60.8% of all patients with CF in the
United States who were culture positive for P. aeruginosa re-
ceived inhaled tobramycin as maintenance therapy (6).
Polypeptide antibiotics of the polymyxin class delivered by
aerosol have been widely used in Europe with reports of uncon-
trolled clinical studies (273–275) using doses of 500,000 to 1
million IU of colistin twice daily (potency of 30,000 IU/mg) for
several months. Such therapy has been associated with decreases
in isolation of P. aeruginosa and possible slowing of decline in
FVC.Arandomizedtrial comparinginhaledtobramycin(300mg
twice daily) and colistin (80 mg twice daily) for 28 days in 109
patients older than 6 years of age demonstrated a 6.7% improve-
mentinthetobramycin-treatedgroupnotobservedinthecolistin
group (276). Both therapies demonstrated a comparable small
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TABLE 3. ANTIBIOTICS FOR THE OUTPATIENT MANAGEMENT OF CYSTIC FIBROSIS
Pathogen Antibiotic Pediatric Dose* Adult Dose
Staphylococcus aureus Choose one:
Dicloxacillin 6.25–12.5 mg/kg four times daily 250–500 mg four times daily
Cephalexin 12.5–25 mg/kg four times daily 500 mg four times daily
Amoxicilin/clavulanate† 12.5–22.5 mg/kg of amoxicillin 400–875 mg of amoxicillin
component twice a day component twice a day
Erythromycin (base) 15 mg/kg three times a day 500 mg twice a day
Clarithromycin 7.5 mg/kg twice a day 500 mg twice a day
Azithromycin 10 mg/kg initial dose followed by 500 mg initial dose followed by
5 mg/kg every day 250 mg every day
Clindamycin‡ 3.5–7 mg/kg three times a day 150–450 mg three times a
day–four times daily
Haemophilus influenzae Choose one:
Amoxicillin 25–50 mg/kg twice a day 500–875 mg twice a day
Amoxicilin/clavulanate† 12.5–22.5 mg/kg of amoxicillin 400–875 mg of amoxicillin
component twice a day component twice a day
Second/third generation cephalosporins:
Cefuroxime axetil 15–20 mg/kg twice a day 250–500 mg twice a day
Cefprozil 7.5–15 mg/kg twice a day 250–500 mg twice a day
Cefixime 4 mg/kg twice a day 200–400 mg twice a day
Cefpodoxime proxetil 5 mg/kg twice a day 100–200 mg twice a day
Loracarbef 7.5–15 mg/kg twice a day 400 mg twice a day
Pseudomonas aeruginosa Choose one:
Ciprofloxacin 10–15 mg/kg twice a day 500–750 mg twice a day
Tobramycin via inhalation 300 mg by nebulizer, twice a day 300 mg by nebulizer, twice a day
Colistin via inhalation 150 mg by nebulizer, twice a day 150 mg by nebulizer, twice a day
Burkholderia cepacia Choose one:
Trimethoprim/sulfamethoxazole 4–5 mg/kg of trimethoprim 160 mg of trimethoprim
component twice a day component twice a day
Doxycycline 5 mg/kg initial dose followed by 200 mg initial dose followed by
2.5 mg/kg twice a day§ 100 mg twice a day
Minocycline 4 mg/kg initial dose followed by 2 200 mg initial dose followed by
mg/kg twice a day§ 100 mg twice a day
Definition of abbreviation: MRSA  methicillin-resistant S. aureus.
This list is not intended to be exhaustive.
All doses are oral unless otherwise noted. Most doses are expressed as milligrams per kilogram of body weight.
* The dose given to children should not exceed that for adults.
† Higher doses of clavulanate are frequently associated with diarrhea.
‡ Clindamycin may be useful for community-acquired MRSA, depending on susceptibility testing.
§ Tetracycline antibiotics are not recommended for children under 8 years of age.
sults of this unblinded study may have been biased by the prior
long-term treatment of most study subjects with inhaled colistin.
There have been reports of bronchoconstriction and chest tight-
ness with colistin inhalation both in adults (277) and children
(278).
There is ongoing interest in developing other classes of in-
haledantibiotics tocomplement inhaledtobramycin andcolistin.
To date, no randomized, placebo-controlled trials of inhaled
-lactams have been reported, and thus it is not possible to
evaluate the efﬁcacy and safety of this antibiotic class. One single
center, open-label study has evaluated aerosol administration of
aztreonam, a monobactam antibiotic, for treatment of patients
with CF colonized with P. aeruginosa (279). In this study, 19
patients with CF (4–20 years of age) were treated for up to 18
months with inhaled doses of aztreonam (500 mg to 1 g) adminis-
tered twice daily. Pseudomonal density declined in 15 of 16 pa-
tients who completed the trial, and several patients had improved
lung function. Transient antibiotic resistance to aztreonam was
observed in 10 patients, and 1 patient had a hypersensitivity
reaction to the drug. Systemic administration of aztreonam for
treatment of Gram-negative infections including P. aeruginosa
has been well tolerated and efﬁcacious in patients with CF (280,
281). Early phase trials of a new formulation of inhaled aztreo-
namarecurrentlyinprogress(B.Montgomery,personalcommu-
nication).
Oneoftheongoingconcernsaboutmaintenance-inhaledanti-
biotic regimens has been emergence of antibiotic resistance
among bacterial pathogens residing in respiratory secretions of
the individual receiving the therapy (282). The impact of chronic
administration of inhaled aminoglycosides on respiratory micro-
bial ﬂora and mechanisms of aminoglycoside resistance was best
studied in the Phase III–inhaled tobramycin trials (283, 284).
The percentage of patients receiving inhaled tobramycin that
yieldedP. aeruginosaisolates withminimal inhibitoryconcentra-
tions of at least 8 g/ml (deﬁned as resistant) increased from 25
to 32%. This increase was not observed in patients receiving
placebo. This change in antibiotic susceptibility had no observ-
able impact, however, on clinical improvement in 6 months of
therapy (197). The primary mechanism for resistance was bacte-
rial wall impermeability (284). There was no evidence of in-
creased isolation of other inherently resistant Gram-negative
pathogens (e.g., B. cepacia), but oral colonization with fungal
pathogens, Aspergillus species and Candida albicans, was in-
creased in the patients receiving inhaled tobramycin (197). Un-
fortunately, since the completion of this Phase III trial, no ongo-
ing studies of antibiotic resistance in the CF population are
available. The long-term impact on respiratory ﬂora is unknown
and should be monitored.
Fluoroquinoloneshave severalcharacteristicsthat havemade
them appealing for oral maintenance therapy. Ciproﬂoxacin,
the most commonly used quinolone in CF, possesses a broad-
spectrum antibacterial activity with excellent bacteriocidal activ-
ity against P. aeruginosa strains isolated from individuals with
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TABLE 4. ANTIBIOTICS FOR THE TREATMENT OF BACTERIA ASSOCIATED WITH PULMONARY EXACERBATIONS
Prevalent Bacteria Antibiotic Pediatric Dose* Adult Dose*
Staphylococcus aureus Cefazolin 30 mg/kg intravenously every 8 h 1 g intravenously every 8 h
OR
Nafcillin† 25–50 mg/kg intravenously every 6 h 2 g intravenously every 6 h
Methicillin-resistant S. aureus Vancomycin‡ 15 mg/kg intravenously every 6 h 500 mg intravenously every6hO R
1 g intravenously every 12 h
Pseudomonas aeruginosa -lactam (choose 1):
Ceftazidime 50 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Ticarcillin§ 100 mg/kg intravenously every 6 h 3 g intravenously every 6 h
Piperacillin 100 mg/kg intravenously every 6 h 3 g intravenously every 6 h
Imipenem  15–25 mg/kg intravenously every 6 h 500 mg–1 g intravenously every 6 h
Meropenem  40 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Aztreonam 50 mg/kg intravenously every 8 h 2 g intravenously every 8 h
PLUS aminoglycoside (choose 1):
Tobramycin¶ 3 mg/kg intravenously every 8 h 3 mg/kg intravenously every 8 h
Amikacin** 5–7.5 mg/kg intravenously every 8 h 5–7.5 mg/kg intravenously every 8h
Burkholderia cepacia Meropenem 40 mg/kg intravenously every 8 h 2 g intravenously every 8 h
PLUS (choose 1):
Minocycline 2 mg/kg intravenously or orally every 100 mg intravenously or orally every
12 h†† 12 h
Amikacin** 5–7.5 mg/kg intravenously every 8 h 5–7.5 mg/kg intravenously every 8 h
Ceftazidime 50 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Chloramphenicol‡‡ 15–20 mg/kg intravenously every 6 h 15–20 mg/kg intravenously every 6 h
Trimethoprim/sulfamethoxazole 4–5 mg/kg of trimethoprim component 4–5 mg/kg of trimethoprim component
intravenously every 12 h intravenously every 12 h
Note: Third drug may be added if synergy
testing suggests efficacy
Stenotrophomonas maltophilia Ticarcillin/clavulanate 100 mg/kg of ticarcillin component 3 g of ticarcillin component
intravenously every 6 h intravenously every 6 h
OR
Trimethoprim/sulfamethoxazole 4–5 mg/kg of trimethoprim component 4–5 mg/kg of trimethoprim component
intravenously every 12 h intravenously every 12 h
OR
Ticarcillin/clavulanate PLUS 100 mg/kg of ticarcillin component 3 g of ticarcillin component
intravenously every 6 h intravenously every 6 h
Aztreonam 50 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Achromobacter xylosoxidans Chloramphenicol‡‡ 15–20 mg/kg intravenously every 6 h 15–20 mg/kg every 6 h
PLUS Minocycline 2 mg/kg intravenously or orally every 100 mg intravenously or orally every
12 h†† 12 h
OR
Ciprofloxacin 15 mg/kg intravenously or orally every 400 mg intravenously or 500–750 mg
12 h orally every 12 h
PLUS (choose 1):
Imipenem 15–25 mg/kg intravenously every 6 h 500 mg–1 g intravenously every 6 h
Meropenem 40 mg/kg intravenously every 8 h 2 gm intravenously every 8 h
Most doses are expressed as milligrams per kilogram of body weight.
* The dose given to children should not exceed that for adults.
† To minimize phlebitis, nafcillin should be diluted to a concentration of less than 20 mg/ml.
‡ Vancomycin should be infused slowly to avoid histamine release. Serum concentrations should be monitored; the peak concentration ranges from 20–40 g/ml,
and the trough from 5–10 g/ml.
§ Ticarcillin may be associated with occasional platelet dysfunction. Its use is limited by concern about the possibility of selection for resistant organisms, such as
S. maltophilia and B. cepacia.
  These drugs are for patients with sensitivity to cephalosporin or multidrug-resistant organisms.
¶ Serum concentrations should be monitored; the peak concentration ranges from 8–12 g/ml, and the trough concentration is less than 2 g/ml.
** Serum concentrations should be monitored; the peak concentration ranges from 20–30 g/ml, and the trough concentration is less than 10 g/ml.
†† Should not be given to patients under 8 years of age.
‡‡ Serum concentrations should be monitored; the peak concentration ranges from 15–25 g/ml, and the trough from 5–15 g/ml.
macokinetic studies (287) in CF demonstrate excellent oral ab-
sorption and bioavailability in airway secretions with subjects
attaining sputum concentrations above the minimal inhibitory
concentration of 90% of all P. aeruginosa isolates for up to 15
hours. Early clinical studies of ciproﬂoxacin monotherapy in
adults with CF experiencing pulmonary exacerbation demon-
stratedimprovedpulmonaryfunction(288)insomecasescompa-
rable with intravenous antibiotics (289, 290). Emergence of
P. aeruginosa and S. aureus resistant to ciproﬂoxacin and other
quinolones is a growing concern and appears to be associated
with monotherapy for more than 3 to 4 weeks (291). Thus,
prolongedtreatmentisdiscouraged.Thequinolonesafetyproﬁle
in adults is very good (292), but the drug is not Food and Drug
Administration approved for use in prepubescent children be-
cause of arthropathy demonstrated in an animal model (293).
However, administration of ciproﬂoxacin to over 3,000 children,
the majority with CF, has been associated with a very low inci-
dence of arthropathy (294–296). Several new ﬂuoroquinolones
(moxiﬂoxacin and gatiﬂoxacin) have become available in recent
years. These drugs may enhance activity for some ciproﬂoxacin-
resistant pathogens, but provide little advantage for P. aerugi-
nosa (297). Thus, ciproﬂoxacin should remain the quinolone of
choice for P. aeruginosa infection in CF, reserving the newer
quinolones for organisms unresponsive to ciproﬂoxacin therapy.State of the Art 933
TABLE 5. PULMONARY EXACERBATION
I Symptoms
A Increased frequency, duration, and intensity of cough
B Increased or new onset of sputum production
C Change in sputum appearance
D New onset or increased hemoptysis
E Increased shortness of breath and decreased exercise tolerance
F Decrease in overall well-being—increased fatigue, weakness, fever, poor appetite
II Physical signs
A Increased work of breathing—intercostal retractions and use of accessory muscles
B Increased respiratory rate
C New onset or increased crackles on chest examination
D Increased air trapping
E Fever
F Weight loss
III Laboratory findings
A Decrease in FEV1 of 10% or greater compared with best value in previous 6 months
B Increased air trapping and/or new infiltrate on chest radiograph
C Leukocytosis
D Decreased SaO2
Macrolidessuchaserythromycin,clarithromycin,andazithro-
mycin have been effective in treatment of chronic airway infec-
tions with P. aeruginosa. This clinical effect was ﬁrst demon-
strated in diffuse panbronchiolitis in Japanese adults (298, 299)
and more recently in studies of patients with CF (267, 300, 301).
In both of these chronic progressive pulmonary disorders, P.
aeruginosa may establish an antibiotic-resistant bioﬁlm where
organisms may evade antibiotics and host lung defenses (97,
132, 133, 137, 302). On the basis of in vitro studies, several
antiinfective and antiinﬂammatory modes of action have been
proposed to account for the efﬁcacy of macrolides in this setting
(303). Antimicrobial effects are augmented by excellent bioﬁlm
penetration and intracellular accumulation in P. aeruginosa, en-
abling inhibition of protein synthesis (304) and improved killing
ofstationaryphaseorganisms(B.Iglewski,personalcommunica-
tion). Macrolides also accumulate within neutrophils impacting
several key functions including oxidant production, apoptosis,
inﬂammatory cytokine production, and macrophage-activating
complex-1 expression (305). Two recent reports of Phase II,
randomized, placebo-controlled trials in children (267) and
adults (301) both demonstrated improved lung function (FEV1)
and fewer respiratory exacerbations, whereas only one report
(301) demonstrated an antiinﬂammatory effect (reduced C-reac-
tive protein serum levels). A larger, Phase III, randomized, con-
trolled trial involving 185 subjects, mean age 20 years colonized
with P. aeruginosa has recently been reported (306). Subjects
received 6 months of thrice weekly azithromycin (500 mg thrice
weeklyforpatients
40kgand 250mgthriceweeklyforpatients
25–40 kg) or placebo. The treatment effect for the primary out-
come, FEV1, was 0.098 L or 6.2% in terms of relative change.
The azithromycin-treated group also demonstrated increased
weight gain and decreased rate of pulmonary exacerbations.
On the basis of the results of these recent studies, the use of
macrolides as a maintenance therapy in patients with CF greater
than6yearsofageandcolonizedwithP.aeruginosaisincreasing.
Future studies are necessary to understand the long-term impact
of this therapy and the efﬁcacy in younger patients with early
disease. There is also a need for in vitro studies to better under-
stand the mechanism of action of macrolides in this setting.
Regular monitoring of airway secretions for presence of nontu-
berculous mycobacteria is recommended because of the concern
for emergence of macrolide resistance in these pathogens.
Treatment of Pulmonary Exacerbation
Once chronically infected with bacterial pathogens such as
P. aeruginosa, individuals with CF experience daily respiratory
symptoms. However, the intensity of these symptoms vary and
these patients will periodically experience pulmonary exacerba-
tions (Table 5). The etiology of a pulmonary exacerbation is
likely a variety of airway insults including respiratory viral infec-
tions, reactive airway disease, and pollutants (307). In addition
to acute morbidity, repeated exacerbations may have long-term
negative impact on lung function and lifespan (194). Thus, opti-
mal treatment of these episodes of increased symptomatology
is an essential component of CF care. Despite the importance
of exacerbations in this illness, no standardized deﬁnition or
criteria has been universally accepted (187, 308). Recent trials
using frequency of exacerbation as a primary outcome measure
have contributed most to a standard deﬁnition (196, 197, 308, 309).
Patients may experience some symptoms and signs of an
exacerbation but are not sufﬁciently ill to warrant intravenous
antibiotics or hospitalization. There are no controlled trials de-
ﬁning the optimal therapy in this setting of a mild pulmonary
exacerbation. In general, patients are treated on an outpatient
basis with oral or inhaled antibiotics on the basis of microbiologic
culture results (Table 3) as well as augmentation of airway clear-
ance, bronchodilators, and, at times, antiinﬂammatory therapy.
For patients meeting most criteria of an exacerbation, stan-
dard therapy includes intravenous administration of two antibi-
otics for 14 to 21 days (310). It is common for these individuals
to require hospitalization and multiple therapeutic interventions
including either oral or parenteral nutritional support, frequent
airwayclearancetechniques,augmentedbronchodilatortherapy,
and corticosteriods. Therapy is usually initiated in the hospital to
monitor aminoglycoside levels and assure stability of respiratory
status. Completion of intravenous therapy at home is common-
place and appears to be as effective as inpatient management
with proper training and supervision (311).
Choice of appropriate antimicrobial therapy should be based
on review of recent cultures of airway secretions. The most
common antibiotic and appropriate dosage regimens for patho-
gens frequently associated with an exacerbation are listed in
Table 4. In the clinical setting of an acute pulmonary infection,
antibiotic efﬁcacy is measured by eradication of the pathogen
and resolution of the inﬂammatory response (312). With chronic
infection, eradication of P. aeruginosa is a rare occurrence. Most
patients, however, experience improvement in respiratory symp-
toms (313). Clinical efﬁcacy is measured by improved pulmonary
function (314, 315) reduction in sputum bacterial density (314,
316), sputum DNA content (316), and improved quality of life
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is recommendedto provide synergyand slow emergenceof resis-
tance (318). A wide variety of -lactams and aminoglycoside
regimens have been studied, with all showing similar efﬁcacy if
administered to individuals with susceptible pathogens (313).
An increasing number of patients with chronic P. aeruginosa
infection develop multiresistant strains deﬁned as demonstrating
resistance to all drugs in at least two out of three major classes
of antipseudomonal antibiotics, -lactams, aminoglycosides, and
quinolones. In this setting, clinicians are encouraged to send
the pathogens to a specialized laboratory that provides synergy
studies (319, 320) or multiple combination bactericidal testing
(238) (see Antibiotic Susceptibility Testing). Optimal choice
in antibiotics should be based on the results from the reference
laboratory.
Thepharmacokineticsofintravenousantibiotics,inparticular
aminoglycosides, have been widely studied and reviewed (321,
322). Patients with CF have a larger volume of distribution and
more rapid renal clearance of many antibiotics, requiring higher
doses to achieve appropriate peak serum concentrations (323).
Thus, close monitoring of serum levels is recommended to mini-
mize risk of renal and ototoxicity. Aminoglycosides have tradi-
tionally been administered thrice daily. Because this class of
antibiotics demonstrates a prolonged postantibiotic effect and
bacterial killing is dependent on peak serum concentration, sin-
gle administration of the total daily dose has been advocated.
By contrast, toxicity is related to trough antibiotic concentration
(324, 325). There have been several studies in CF populations
comparing thrice-daily (3.3 mg/kg dose), once-daily (10 mg/kg
dose), and in some cases twice-daily (5 mg/kg dose) regimens
(324–327). All studies have shown comparable improvement in
lung function, but none has been large enough to demonstrate
equivalency. There has been no evidence of increased oto- or
nephrotoxicity in over 100 patients receiving once-daily therapy.
Thereisnosufﬁcientenough long-termdatatoassessdifferences
in rate of emergence of resistant P. aeruginosa. Once-daily amino-
glycoside dosing appears to increase the peak concentration to
well above the minimal inhibitory concentration of 90% of most
P. aeruginosa but may also increase the time below the minimal
inhibitory concentration (327). Which of these parameters is
more important for long-term efﬁcacy is not known.
To monitor aminoglycoside values for standard thrice-daily
(every8hours)administration(initialdose3.3mg/kg),twometh-
odsmaybe used(328).Tousethe “initialdosepharmacokinetic”
method, the patient is given the ﬁrst intravenous dose over 30
minutes and two or three accurately timed serum levels are
drawn beginning 1 hour after initiation of the infusion. Pharma-
cokinetic analysis can be used to predict the dose necessary to
achieve the desired peak (10–12 mg/L). Use of the alternative
“peak level” method is based on the assumption that patients
with CF have normal renal function. After three to ﬁve dose
intervals, a peak level is collected 30 minutes after a 30-minute
intravenousinfusionandthedoseisadjustedtoreachthedesired
peak value of 10 to 12 mg/L. By either method, a trough level
drawn before the next dose should be less than 2 mg/L.
With once-daily administration aminoglycoside dosing (10
mg/kg day), the peak levels (20–60 mg/L) far exceed the custom-
ary serum targets noted previously and yet are not associated
with documented increased oto- or nephrotoxicity. These data
callintoquestionthevalueofmonitoringpeakserumtobramycin
levels. The Cystic Fibrosis Foundation care guidelines (167) rec-
ommend weekly tobramycin serum trough levels and creatinine
for individuals receiving intravenous (not inhaled) aminoglyco-
sides irrespective of whether the patient is hospitalized or receiv-
ing home therapy. Routine monitoring of serum tobramycin
levels is not recommended for patients with normal renal func-
tion receiving only inhaled tobramycin (329). Monitoring for
eighth cranial nerve toxicity should include an audiogram (500–
8,000 Hz range) after every two to four courses of intravenous
therapy (aerosol antibiotic) (272).
Treatment of Other Emerging Pathogens
B. cepacia complex. B. cepacia complex organisms are often
highly antibiotic resistant. All are intrinsically resistant to the
aminoglycosides (330). The rate of in vitro resistance to the
-lactam antibiotics, with the exception of meropenem, is also
quite high (331, 332). The quinolones appear to have variable
activity, but resistance can be readily induced (332). In vitro
susceptibility testing suggests that there are combinations of
antibiotics that act synergistically against B. cepacia complex
using either synergy testing (333) or multiple combination bacte-
ricidal testing (331). Synergy testing, using two drug combina-
tions, found that for 57% of isolates tested, no active combina-
tion could be identiﬁed. The most active combinations were
chloramphenicol plus minocycline (49% of isolates) and chlor-
amphenicol plus ceftazidime (26% of isolates) (333). Multiple
combination bactericidal testing using two or three drug combi-
nations, determined that at least one 2 or 3 drug combination
could be identiﬁed for all isolates tested (331). The most active
combinations are listed in Table 4. The majority of active combi-
nations included meropenem. Unfortunately, it was not possible
to predict for a given isolate whether a drug combination would
besynergistic,additive,orantagonistic(331);thus,invitrotesting
atreferencelaboratoriesisrecommended(mcbt@cheo.on.caand
synergy@columbia.edu).
OtherresistantGram-negatives.Otherantibiotic-resistantGram-
negative CF isolates include S. maltophilia and A. xylosoxidans.
Treatment of these organisms is often complicated by resistance
to the aminoglycosides and variable susceptibility to the -lac-
tams and quinolones. For both of these organisms, therapy should
be directed by susceptibility testing. The most active single drugs
in vitro against S. maltophilia are ticarcillin/clavulanate and tri-
methoprim/sulfamethoxazole; the most active combination in
synergy studies is ticarcillin/clavulanate plus aztreonam (334).
S. maltophilia is routinely resistant to imipenem and meropenem
(335). In a study of 106 CF isolates of A. xylosoxidans, the
mostactivedrugswereimipenem(59%susceptible),piperacillin/
tazobactam (55%), meropenem (51%), and minocycline (51%)
(319). The most active additive or synergistic combinations were
chloramphenicol plus minocycline, ciproﬂoxacin plus imipenem,
and ciproﬂoxacin plus meropenem.
Nontuberculous mycobacteria. Treatment guidelines for the
management of nontuberculous mycobacteria are evolving as
more information becomes available on the epidemiology and
clinical course of patients with CF culturing these organisms
(165,166).Currentrecommendationsarethatadultpatientswith
CF be screened on a regular basis and, if there are ﬁndings
suggestive of infection rather than colonization, antimycobacte-
rialtherapyofatleast1year’sdurationisindicated(336).Speciﬁc
drugs that are active against the most common organisms are
listed in Table 6. Multiple drug therapy is recommended with
sequential addition of drugs over 1 to 2 weeks to monitor side
effects. Monitoring of drug levels may be useful because of
altered drug metabolism in CF. In vitro susceptibility testing
is recommended for non–M. avium complex organisms or if
patients are not responding over a 6-month period (http://
research.uthct.edu/).
Immunotherapy
Although signiﬁcant advances in vaccine development directed
against bacterial pathogens have occurred over the past decades
(337), active immunotherapy to prevent or ameliorate P. aerugi-
nosa infection in CF has not been achieved. The unique charac-
teristics of both the host and pathogen (see Impact of DefectiveState of the Art 935
TABLE 6. THERAPY OF NONTUBERCULOUS MYCOBACTERIA
Organism Agents Dosing (Route) Monitoring
Mycobacterium avium intracellulare complex Clarithromycin 15–30 mg/kg/d orally divided twice a day, Levels decreased by rifampin/rifabutin
m a x1g
Rifampin 10–20 mg/kg/d orally, max 600 mg Monitor CBC
Rifabutin 5–10 mg/kg/d orally, max 300 mg Monitor CBC
Ethambutol 25 mg/kg/d orally Monitor color vision and acuity
CONSIDER: Streptomycin 500–750 mg two to three times/wk Monitor renal function, audiometry
intravenously for first 8 weeks if severe
Mycobacterium abscessus Cefoxitin 200 mg/kg/d intravenously divided every Monitor CBC
8 h, max 12 g
Amikacin 10–15 mg/kg/d intravenously divided Monitor serum levels, renal function,
every 12 h audiogram
Clarithromycin 15–30 mg/kg/d orally divided twice a day, Levels decreased by rifampin/rifabutin
m a x1g
CONSIDER: Surgical debridement if
infection is localized
Definition of abbreviation: CBC  complete blood count (with differential).
Most doses are expressed as milligrams per kilogram of body weight.
CFTR on Initial and Persistent P. aeruginosa Infection and
Characteristics of P. aeruginosa That Contribute to Initial
and Persistent Infections) have made vaccine development
challenginginthis illness.PatientswithCFare capableofmount-
ing a vigorous antibody response to surface polysaccharides such
as mucoexopolysaccharides (338) and exoproducts (107–109,
241) of P. aeruginosa. Initial antibody response to surface pro-
teins may actually precede evidence of chronic P. aeruginosa
infection or lung disease (107, 108) and likely prevent systemic
disease. Yet, the immune response is not effective in eradicating
the organism from the airway possibly because naturally ac-
quired antibodies have low afﬁnity with poor opsonic activity
(110, 339). In fact, high antibody titers are associated with more
severe lung disease (302). P. aeruginosa is also a challenging
pathogen because most patients are initially colonized with
unique environmental strains (126). Thus, developing a vaccine
directed against one or a few capsular polysaccharides (e.g., H.
inﬂuenzae type b) may not be widely effective. During chronic
infection, P. aeruginosa also changes its surface polysaccharide
structure, losing O-side chains from LPS and producing muco-
exopolysaccharide, which reduces its antigenicity (115) and in-
creases its resistance to phagocytosis.
Early studies of polyvalent Pseudomonas vaccines were not
effective in delaying colonization with the pathogen and may
have predisposed some patients to more severe pulmonary dis-
ease once infected (340). More recently, an octavalent P. aerugi-
nosa O-polysaccharide toxin, a conjugate vaccine, appears to be
well tolerated and capable of inducing high afﬁnity, opsonic anti-
LPS antibodies in young noncolonized patients (341). Protection
against P. aeruginosa infection, however, was seen in only a
subgroup of patients (342). No Phase III efﬁcacy studies have
been conducted to evaluate the impact of this vaccine on preven-
tion of P. aeruginosa infection. A ﬂagellar vaccine has also been
shown to elicit long-lasting antibodies and a Phase III trial is
currently in progress in Europe (343). Alginate-based vaccines
directed against mucoid variants of P. aeruginosa have also been
developedbuthavehadlimitedimmunogenicity(344).Itislikely
that the most efﬁcacious approach to immunotherapy in CF in
the future will be the induction of mucosal immunity in young
patients before colonization with P. aeruginosa (337).
Patients with CF are immunocompetent and mount appro-
priateantibodyresponsetocurrentlyavailableviralandbacterial
vaccines. They should receive all routine immunizations recom-
mended by the American Academy of Pediatrics (345). It is
importantthatCFspecialistsandprimarycarephysicianscoordi-
nate efforts to ensure that patients with CF receive age-appro-
priateimmunizations.Althoughthesepatientsdonotexperience
increased incidence of respiratory infection associated with
Streptococcus pneumoniae and H. inﬂuenzae type b, they should
receive these vaccines as per American Academy of Pediatrics
recommendations. It is also recommended that individuals with
CF receive an annual inﬂuenza virus vaccine (345).
INFECTION CONTROL IN CF PULMONARY DISEASE
Infection control is an important topic in the management of CF
airway infection. In June of 2001, the Cystic Fibrosis Foundation
conveneda multidisciplinaryconsensus conferenceof healthcare
professionals from the United States, Canada, and Europe in-
cluding infection control practitioners, CF caregivers, microbiol-
ogists, and infectious disease specialists to make CF-speciﬁc
recommendations for infection control policies (346).
Transmissibility of CF Pathogens
In general, transmission of CF pathogens occurs by droplet and
contact routes, thus infection control strategies must be directed
at these routes. Both standard precautions and transmission-
based precautions should be applied to patients with CF. One
of the most important issues related to CF infection control is
that infection control practices cannot be implemented on the
basis of the speciﬁc microbiology results for individual patients
because current bacteriologic methods are not 100% sensitive
for real-time detection of the myriad of organisms that may be
present.
B. cepacia. Person-to-person transmission of B. cepacia com-
plex among patients with CF has been demonstrated both in
healthcare and social settings (347–350). Whereas contact trans-
mission has been clearly documented, and droplet transmission
is likely, airborne transmission of B. cepacia complex has not
beendocumented.Twospeciﬁc virulencefactorshavebeenasso-
ciated with transmission of genomovar III isolates, cable pilus,
and the B. cepacia epidemic strain marker (148, 351). The reser-
voirs of B. cepacia include sites within the healthcare setting
that may have been contaminated by patient contact (349, 352–
355) and natural environments such as the soil (356). B. cepacia
suspended in CF sputum may survive for over 24 hours on
environmental surfaces such as latex or polyvinylchloride tubing
of respiratory equipment (357).
The epidemiology of B. cepacia is perhaps the best studied
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TABLE 7. SUMMARY OF INFECTION CONTROL RECOMMENDATIONS FOR HEALTHCARE SETTINGS
Setting Recommendation Category*
General principles Assume all patients with CF could have transmissible pathogens and apply Standard precautions IA
Implement transmission-based precautions according to CDC/HICPAC published recommendations IA
Healthcare workers should use approved methods of hand hygiene IA
Gloves should be worn when caring for patients who require Contact or Droplet precautions IA
Gowns should be worn as defined by Standard or pathogen-specific precautions IB
Published recommendations for sterilization and disinfection of patient care equipment should be followed IA
Wall humidifiers and “in-line” and hand-held nebulizers should be cleaned and dried according to IB
manufacturer’s recommendations; disposable and single-use items should be discarded after use
PFT equipment should use disposable in-line bacterial filters in between each patient; disposable II
mouthpieces are preferred; sterilization of the internal machinery of PFT machines is not needed
between patients
In ambulatory care settings, examination room surfaces should be cleaned after the room is vacated; IB
regular cleaning of other surfaces should be on a regular basis and as soiling occurs
Microbiology and surveillance Respiratory tract cultures should be performed at least quarterly and processed for culture and susceptibility IB
according to CF-specific guidelines
All Burkholderia cepacia complex isolates should be confirmed and speciated at the Cystic Fibrosis Foundation IB
Burkholderia cepacia Research Laboratory and Repository (University of Michigan)
Surveillance strategies should be developed in collaboration with the institutional infection control team IB
Molecular typing using approved genotyping methods should be performed as epidemiologically indicated IA
Inpatient All patients with CF with B. cepacia complex, MRSA, or VRE should be housed in single-patient rooms that IA
do not share common facilities (e.g., bathroom, shower)†
Patients with CF without the above organisms may share rooms with patients without CF who are low II
risk for infection†
Patients not on transmission-based precautions may be evaluated for activity outside their hospital room II
as long as they are educated according to hand hygiene and avoidance of direct contact with other
patients with CF, and with appropriate disinfection of surfaces
Ambulatory Develop a reliable method for tracking patients’ most recent culture and susceptibility testing results IB
Alert other diagnostic areas of patients’ transmission precautions IB
Manage scheduling to minimize time in common waiting areas II
Encourage hand hygiene and have waterless antiseptics or other products available for use by patients IA
Discourage use of common items in waiting area that cannot be cleaned between patients (e.g., toys, II
computer)
Observe Contact plus Standard precautions for epidemiologically important pathogens (e.g., B. cepacia IA
complex, MRSA, multidrug-resistant Pseudomonas aeruginosa)
Segregate patients infected with B. cepacia complex, and place patients with multidrug-resistant IB
P. aeruginosa in room immediately
Definition of abbreviations:C F cystic fibrosis; HICPAC  Hospital Infection Control Practices Advisory Committee; MRSA  methicillin-resistant Staphylococcus aureus;
PFT  pulmonary function testing; VRE  vancomycin-resistant Enterococcus.
Data from Reference 346.
* Categories are based on the CDC/HICPAC system. Category IA: strongly recommended for implementation and strongly supported by well designed experimental,
clinical, or epidemiologic studies. Category IB: strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and
a strong theoretic rationale. Category II: suggested for implementation and supported by suggestive clinical or epidemiologic studies or a theoretic rationale.
† Patients with CF who sleep in the same room at home may share a hospital room (Category II).
interventions have been successful in interrupting transmission
(348, 352, 353, 358–361). Interventions that have been successful
(in various combinations) include segregation of patients, dis-
couraging socializing between infected patients, emphasizing
hand hygiene, and improving education of patients, families, and
caregivers.
P. aeruginosa. As discussed in Phenotypic Changes, each
patient is initially colonized with unique environmental strains
(107, 126). P. aeruginosa appears to have a very different pattern
of transmissibility in patients with CF compared with B. cepacia.
Most frequently, clonal strains are shared only among siblings
and patients linked socially (such as close friends or individuals
in camp settings) (125, 126, 362). However, there are reports of
patient-to-patient transmission in healthcare settings including
clusters of multiply-resistant isolates; when documented, trans-
mission has been successfully interrupted by implementation of
infection control measures (363–365). P. aeruginosa in CF spu-
tum may persist on a polyvinyl surface at least for 5 days (366).
Consensus Recommendations
The speciﬁc recommendations of the consensus conference on
infection control in CF (346) are summarized in Table 7. They
are “graded” according to the evidence available and are based
on both general principals of infection control and CF-speciﬁc
clinical situations.
These recommendations include policies for the care of pa-
tients in both the inpatient and outpatient settings as well as
proper care of respiratory equipment in all settings. There are
also guidelines for patients and families outside the hospital/
clinic environment where multiple patients may interact. The
augmentation of infection control procedures in recent years at
CF care centers worldwide has and will continue to impact on
the lives of patients and families. For this reason there is a need
for ongoing patient, family, and staff education regarding the
goalsofinfectioncontrol.Thereisalsoacriticalneedformicrobi-
ologic surveillance studies to document the impact of infection
control policies on bacterial cross-infection.
CURRENT THERAPIES TO OPTIMIZE AIRWAY
CLEARANCE AND REDUCE INFLAMMATION
Optimizing Airway Clearance and ASL Hydration
Assisting mechanical clearance of viscous airway secretions with
airway clearance techniques is a cornerstone of managing estab-State of the Art 937
lished CF pulmonary disease. Standard chest physiotherapy in-
volves postural drainage with chest percussion in several ana-
tomic positions to favor gravitational clearance of secretions
from all lobes of the lungs (367). A short-term, controlled study
showed standard chest physiotherapy improved sputum produc-
tion and lung function in the setting of pulmonary exacerbation
(368). Although, there are no randomized controlled trials in
stable patients with CF comparing chest physiotherapy with
spontaneous cough (369), the long-term beneﬁts of daily mainte-
nance chest physiotherapy are believed by many clinicians and
patients to be beneﬁcial in improving airway clearance.
Newer active and passive techniques have been developed to
providepatients withmore autonomy.Active techniquesinclude
the forced expiratory technique or “huff maneuver” (367, 370),
autogenicdrainage(370),positiveexpiratorypressuremask(367,
371), and oral airway oscillators such as Flutter and Acapella
(372, 373). Passive techniques include high-frequency chest wall
oscillator (374, 375) and an intrapulmonary percussor ventilator
(376). Several small, uncontrolled studies have demonstrated
some improvement in FEV1 and/or clinical scores with several
of the techniques (371, 376, 377). Therefore, with limited com-
parative efﬁcacy data, patient satisfaction and compliance with
a given airway clearance technique are major criteria for select-
ing a form of therapy.
Mucolytics. Recombinant human DNase (Pulmozyme) is the
most widely used treatment to reduce sputum viscosity and is
Food and Drug Administration approved for chronic mainte-
nance therapy in all patients with CF. Puriﬁed recombinant hu-
man DNase I digests polymeric extracellular DNA and reduces
the viscosity of CF sputum specimens (58, 378). The Phase III
trial of Pulmozyme found 2.5 mg nebulized once daily resulted in
6% treatment effect in FEV1 and a 22% reduction in pulmonary
exacerbations requiring intravenous antibiotics (196) in patients
with CF older than 5 years of age and FEV1 greater than 40%.
The primary adverse events believed to be related to the study
drug were transient laryngitis and hoarseness. A subsequent
study showed that daily Pulmozyme therapy in patients with CF
with severe obstructive lung disease resulted in improvement in
lung function over 12 weeks, but no reduction in pulmonary
exacerbations (379). A 2-year randomized controlled trial in
children with CF between 6 and 10 years of age and mild lung
disease showed modest treatment effects in FEV1 ( 3%) and
FEF25–75% ( 8%), but a 34% reduction in pulmonary exacerba-
tions requiring parenteral antibiotics (380, 381). In addition,
once-daily Pulmozyme therapy is safe with adequate lower air-
waydepositioninchildrenlessthan5yearsofage(382).Itseffect
is short lived (383) and not recommended for acute intermittent
usage. There have been no published studies clarifying optimal
timing and sequence for administration of DNase, bronchodila-
tors, and chest physiotherapy. Many clincians recommend a se-
quence of a bronchodilator and DNase followed by chest physio-
therapy on the basis of clinical experience.
Hypertonic saline. Hypertonic saline has a favorable effect
on mucus rheology in vitro (384). Controlled trials of ultrasonic
nebulization of hypertonic saline in stable patients with CF with
moderate obstructive lung disease results in an acute increase
in mucociliary clearance for up to 90 minutes (385, 386). The
effect is dose dependent with greater increases in mucociliary
clearance for increasing saline concentrations of 3, 7, and 12%
compared with control subjects inhaling isotonic saline (386).
Hypertonic saline challenges in stable patients with CF with mild
to moderate obstructive lung disease can cause acute, transient
airﬂow obstruction (227, 387), and the majority of clinical studies
havepretreatedpatientswith-agonistsbeforehypertonicsaline
therapy.A2-weekcontrolledtrialoftwice-dailyultrasonicnebu-
lization of 6% hypertonic saline compared with isotonic saline
showed a signiﬁcant increase in FEV1 (388). Further studies on
long-term efﬁcacy of hypertonic saline therapy, optimal hyper-
tonic saline concentration, and mode of delivery (jet vs. ultra-
sonic nebulizer) are necessary (389).
Bronchodilators
Bronchial hyperresponsiveness occurs in about half the number
ofpatientswithCF(390).Theetiologyofbronchialhyperrespon-
siveness in CF is multifactorial and differs from that in asthma
(391). Response to short-acting inhaled bronchodilators is vari-
able over time and between patients with CF (391, 392); approxi-
mately 50 to 60% patients show improved FEV1, approximately
20to30%patientsshownochange,andapproximately10to20%
patients show reduced lung function (392). Short-term studies in
stable patients with CF are not conclusive but some show acute
increases in lung function especially among patients with CF
with bronchial hyperresponsiveness (391, 392). A short-term
study of albuterol in hospitalized patients with CF showed tran-
sientimprovementinFEV1comparedwithplacebo(393).Longi-
tudinal studies of short-acting -agonists over 1 to 2 years show
that almost all patients demonstrate improvement in FEV1 on
at least oneevaluation, and on average subjects hada bronchodi-
lator response on approximately 25% of the days tested (394,
395). There was no conclusive evidence of clinically signiﬁcant
long-term improvement in lung function for albuterol compared
withplacebo(391,394).Apreliminarystudyofhigh-dosesalmet-
erol plus albuterol compared with albuterol alone in stable pa-
tients with CF found a signiﬁcant treatment beneﬁt in lung func-
tion and respiratory symptoms after 24 weeks with salmeterol
plus albuterol (396).
There are limited and conﬂicting data on the role of ipratro-
prium bromide in the treatment of CF (397–399), but most data
show limited beneﬁt for ipratropirum bromide added to -ago-
nist therapy. With all inhaled therapies, proper selection, use,
and maintenance of meter dose inhalers and nebulizer machines
is critical in ensuring optimal delivery (346, 400–403).
Antiinflammatory Therapy
Several clinical trials of antiinﬂammatory therapy in CF have
shown clear beneﬁt, but unacceptable adverse effects have lim-
ited their use (56). Chronic, alternate-day systemic steroids slow
the decline in lung function but cause signiﬁcant toxicity, includ-
ing an increase in growth retardation, cataracts, and hyperglyce-
mia(404–406).Dataarelackingforshort-termsafetyandefﬁcacy
of systemic corticosteroids for adjunctive therapy of pulmonary
exacerbations in CF. High-dose ibuprofen therapy over 4 years
demonstrated a signiﬁcant reduction in the rate of decline in
FEV1 for patients who were 5 to 12 years old, fewer hospitaliza-
tions, and improved nutritional status (407). Despite this impres-
sive ﬁnding, high-dose ibuprofen is used for fewer than 15% of
eligible patients with CF at U.S. CF Centers (408). Concerns
for the small increased risk of gastrointestinal hemorrhage and
the need to monitor drug levels contribute to reduced ibuprofen
use (409). The mechanism by which ibuprofen attenuates the
decline in lung function is uncertain but is believed to be due
to reduced neutrophil migration in the lung (56). More speciﬁcs
on the mechanism by which ibuprofen preserves lung function
may promote the development of better agents.
The use of inhaled steroids is common in CF (408, 409).
However, unlike asthma, there is no convincing evidence for
a signiﬁcant antiinﬂammatory effect or clinical efﬁcacy in CF
(410–413). The subpopulation of patients with CF with bronchial
hyperresponsiveness may derive some beneﬁt (412). Infants with
CF treated with inhaled steroids for 2 months demonstrated
no adrenal suppression, no signiﬁcant changes in lower airway
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counts (414). Further studies of inhaled steroids are warranted
in young children with CF.
Other antiinﬂammatory agents are less well studied in CF.
Montelukast, a cysteinyl-leukotriene receptor antagonist, was
found to reduce systemic evidence of eosinophilic inﬂammation
in CF, but no data were presented on clinical efﬁcacy (415).
There are ongoing clinical trials of an LTB4 receptor antagonist
(M.Konstan,personalcommunication).Theburdenofproteases
in the CF airway far exceeds the host lung defenses (56). Initial
attempts to fully inhibit the airway protease burden in CF with
-1 antitrypsin and recombinant secretory leukoprotease inhibi-
tors have not been successful (416, 417). The oxidant burden is
also high in the CF airway (56). In a pilot study, twice-daily
aerosolized glutathione increased airway levels of glutathione
and reduced superoxide production from cells recovered in BAL
ﬂuid (418). A pilot study of inhaled S-nitrosoglutathione found
no signiﬁcant adverse events, increased exhaled concentrations
of nitric oxide, and statistically but not clinically signiﬁcant in-
creases in SaO2 (419).
Diagnosis and Treatment of ABPA
A 2001 Cystic Fibrosis Foundation Consensus Conference re-
centlyprovidedadeﬁnedset ofclinicalandlaboratorydiagnostic
criteria (155, 157) to diagnose ABPA in patients with CF. The
full diagnostic criteria are (1) acute or subacute clinical deterio-
ration not attributable to another etiology, (2) serum total IgE
concentration higher than 1,000 IU/ml in patients not receiving
systemic corticosteroids, (3) immediate cutaneous reactivity to
Aspergillus or in vitro presence of A. fumigatus–speciﬁc serum
IgE antibodies, (4) precipitating antibodies to A. fumigatus or
serum A. fumigatus–speciﬁc IgG antibodies by an in vitro test,
and (5) new or recent abnormalities on chest radiograph (inﬁl-
trates, mucus plugging) or chest computerized tomography
(bronchiectasis) that have not cleared with antibiotics and stan-
dardphysiotherapy.Theconsensusstatementalsoprovidesmini-
mal diagnostic criteria to include: criteria (1) and (3) described
previously, a total serum IgE higher than 500 IU/ml, and either
criteria (4) or (5) described previously. This group recommends
annualscreeningwithatotalserumIgEconcentrationinpatients
with CF 6 years and older. If the value is higher than 500 IU/ml,
determine the immediate cutaneous reactivity to A. fumigatus or
determine A. fumigatus–speciﬁc IgE antibodies.
The diagnosis of ABPA remains challenging because there
is signiﬁcant overlap in the clinical features of CF pulmonary
exacerbation and ABPA, and a high proportion of patients with
CF have intermittent serologic features of ABPA without the
full syndrome. Some studies report elevated total IgE or serum-
precipitating antibodies occur in up to 25% of patients with CF
(157), and that up to 60% of patients with CF may have positive
skin tests to A. fumigatus antigens. Availability of recombinant
A. fumigatus antigens in the near future may improve the diag-
nostic accuracy for ABPA and improve our understanding of
the underlying immmunopathogenesis (157).
Corticosteroids arethe mainstay ofABPA therapyin asthma,
and itraconozole provides additional beneﬁt as well as a steroid-
sparing effect (156, 157, 420, 421). There are limited data for
either treatment of ABPA in CF (157). In addition, systemic
steroids have a higher rate of untoward effect in the CF popula-
tion (405). The limited data suggest that initial therapy should
be prednisone, 2 mg/kg/day for 1 to 2 weeks, a taper to 1 mg/
kg for 1 to 2 weeks, with further taper to alternate-day and then
an attempt at discontinuation by 2 to 3 months (155, 157, 422,
423). The decision to taper prednisone is based on clinical im-
provement and reduction in total serum IgE (156, 157, 422, 424,
425). Itraconazole (5 mg/kg up to a maximum of 200 mg twice
a day) can be added if patients show poor clinical or serologic
response to steroids (157, 346, 420, 422, 426, 427). In cases where
clinical response is suboptimal, it is recommended to check se-
rum itraconazole levels (i.e,  1 mg/L) to ensure an adequate
plasma level after 1 to 2 weeks of treatment (157); the total
duration of itraconazole treatment may be up to 3 to 6 months.
Allpatientstreatedwithitraconazoleshouldhaveperiodicmoni-
toring of liver function tests and should review concomitant
medications for drug interactions (346). Although other oral
antifungal therapies such as voriconazole are now available,
therearenodataregardingtheirefﬁcacyandsafetyfortreatment
of ABPA in the CF population. There are no published data
showing the efﬁcacy of inhaled corticosteroids for the treatment
o fA B P Ai nC F .
FUTURE THERAPIES FOR CF PULMONARY DISEASE
Gene Transfer Therapy
Within 1 year of discovering the CF gene, in vitro studies demon-
strated that introduction of CFTR complementary DNA into
affected cells could correct the chloride channel defect (428,
429) and provided evidence that gene transfer therapy might
be effective in CF. Several aspects of this autosomal recessive
disorder favored the success of this approach. First, mature wild-
type CFTR is localized to the apical surface of airway epithelia
and submucosal glands (430) potentially accessible by aerosol
delivery and minimizing systemicexposure. Second, several lines
of evidence suggested that minimal levels of CFTR would be
required to correct the ion channel defect. Respiratory epithelial
cells contain only 1 to 2 CFTR transcripts (431). Mixing experi-
ments indicate that targeting less than 10% of cells could correct
chloride transport (432), but normalization of raised sodium
absorption may require targeting a higher percentage of cells
(433). In addition, individuals with 5 to 10% wild-type CFTR
transcripts have no pulmonary disease (1, 2). Third, an in vivo
assay of ion channel activity, nasal potential difference (NPD)
measurements (26), could provide real-time assessment of func-
tional gene expression.
Early human studies using adenoviral (434–436) and nonviral
cationic lipid (437–439) delivery systems were successful in dem-
onstrating gene expression in upper and lower airway epithelia
by immunocytochemistry (435, 436) and functional assay (NPD)
(434, 437, 439, 440). Although these results are encouraging,
barriers to effective gene transfer therapy including poor efﬁ-
ciency (441) and limited duration (442) of gene expression and
apparent signiﬁcant immune and inﬂammatory response to ade-
noviral vectors were observed (435, 441, 443).
More recent human studies have used an adeno-associated
virus (AAV) serotype 2 vector to deliver CFTR complementary
DNA to respiratory epithelia. Despite limited packaging capac-
ity prohibiting the addition of a strong promoter or regulatory
elements with the CFTR complementary DNA, tissue culture
and animal studies have demonstrated stable expression of
CFTR protein for up to 6 months without pathologic ﬁndings
in animal studies (444, 445). Over 75 patients with CF have
received single or repeated doses of AAV–CFTR to nasal, sinus,
or lower airway epithelia (446, 447). The vector appears to be
safe and well tolerated. Gene transfer at a maximum of 1 copy
per 10 epithelial cells (collected by bronchial brush biopsy) was
observed at 30 days after a single aerosol administration of 1013
DNase-resistant particles but declined to nondetectable at 90
days and no wild-type CFTR messenger RNA expression has
been detected (446). A multicenter, randomized, placebo-con-
trolled trial evaluating the safety and tolerability of three
monthly repeated aerosol administrations of 1013 DNase-resis-
tantparticlesAAV–CFTRwasrecentlycompleted(448).Thirty-
seven patients with mild pulmonary involvement (FEV1  60%)State of the Art 939
received at least one aerosol administration (20 vector, 17 pla-
cebo). There were no safety concerns, but a fourfold or greater
elevation in neutralizing serum antibodies against AAV2 was
defectedinallpatientsreceivingvector(nonereceivingplacebo).
Gene transfer but not gene expression was detected. A mean
improvement in FEV1 of 0.12 L was observed at 30 days in the
treatment group compared with placebo but not at subsequent
time points, i.e., 60, 90, and 150 days.
Thus, initial clinical trials suggest that the AAV2 is safe,
well tolerated, and may be an excellent vehicle for human gene
therapy if the hurdle of poor gene expression can be overcome.
Several in vitro approaches are currently addressing this issue.
Coadministration of AAV2 with a proteosome inhibitor (449)
resultsinimprovedtransgeneexpressionandaugmentednuclear
trafﬁcking of the virus. Other serotypes of AAV, in particular
AAV5 (450) and AAV6 (451), have demonstrated higher trans-
duction efﬁciency in respiratory epithelial cells than AAV2 and
likely use different cell receptors. Finally, smaller CFTR trans-
genes with deletions in the R domain (452) or C-terminus (453)
remain functional and may better accommodate the packaging
capacity of AAV and permit addition of a promoter and other
regulatoryelements.Genetherapyremainsinanevolving,devel-
opmental stage in CF. Some initial human studies with AAV
have been encouraging but signiﬁcant barriers remain before
efﬁcient delivery and long-term expression of the CFTR trans-
gene in the airway are achieved.
Pharmacologic Approaches
The current understanding of normal and mutant CFTR struc-
ture and function has directed investigators to develop therapeu-
tic strategies to partially or fully correct the abnormal protein
or bypass the loss of function through modulation of alternative
ion channels. This section will summarize several of these ap-
proaches and review ongoing early human trials (Phase I/II).
None of these pharmacologic approaches have reached large,
Phase III trials or shown clinical efﬁcacy. Drug development is
an iterative process. It is likely that most early compounds tested
will provide valuable data on safety, pharmacokinetics, and bio-
logic effects but will not reach Food and Drug Administration
approval.
Approaches to correct dysfunctional CFTR. Because the
mechanism of CFTR dysfunction differs by the class of mutation
(Figure 3), treatment regimens will likely be “tailored” toward
each individual patient’s genotype. For this reason, examples of
potential strategies are presented by mutational class.
Mutations leading to defective CFTR biosynthesis (Class I)
due to premature stop codons are found in approximately 10%
of all patients with CF and in much higher frequency among
certain populations such as individuals of Ashkenazi Jewish
decent (16). Some aminoglycosides, in particular gentamicin, are
effective in suppressing premature stop mutations in the CFTR
gene in bronchial epithelial cell lines (454), allowing restoration
of full length CFTR expression and reappearance of cAMP-
activated chloride currents. Two small clinical trials of gentami-
cinadministrationtoindividualswithCFwithatleastoneprema-
ture stop mutation have been reported. An Israeli study (455)
of nine patients with premature stop mutation (seven with two
copies, two with one copy of premature stop mutations) evalu-
atedchangesinNPDmeasurementafter14daysoftopicalgenta-
micin application to nasal mucosa and found signiﬁcant repolar-
ization of nasal epithelium consistent with partial correction of
transmembrane chloride transport under conditions that select
for CFTR function. An American study (24) reported similar
trends in NPD after intravenous administration of gentamicin
for 1 week. In this study, four of ﬁve patients with one copy of
premature stop mutation demonstrated at least one chloride
secretoryresponseofgreaterthan	5mVnotobservedinhomo-
zygous F508 patients. As further evidence of the potential
beneﬁt of gentamicin in this class of mutations, mice possessing a
premature stop codon in the dystrophin gene have demonstrated
restored dystrophin function in skeletal muscle (456).
Because Class II mutations (including F508) are the most
common, there is broad interest in identifying chemical chaper-
ones that facilitate folding, inhibit ubiquitin-mediated degrada-
tion, and promote trafﬁcking of these mutant CFTR proteins to
the cell surface where they retain at least partial function as
chloride channels (20). Many potential compounds such as glyc-
erol (457), anthracycline derivatives (458), butyrates (459), tri-
methylamine oxide (460), and cyclopentyl 1,3-dipropylxanthine
(461) have been tested in cell systems and have shown protein
maturation and trafﬁcking to the cell surface. Phase I random-
ized, double-blind human trials have been reported for oral
sodium 4-phenylbutyrate (462) and cyclopentyl 1,3-dipropylxan-
thine (463). Oral phenylbutyrate was well tolerated for 1 week
at the maximum Food and Drug Administration–approved adult
dose (19 g thrice daily) and some changes in NPD suggestive of
CFTR function were observed. A single-dose escalation study
ofcyclopentyl1,3-dipropylxanthinedidnotdemonstratechanges
in NPD. High throughput screening efforts supported by the
Cystic Fibrosis Foundation are ongoing to identify new chemical
compounds that promote CFTR trafﬁcking and will likely reach
clinical trials in the near future.
For Class III/IV mutations that reach the cell surface or Class
II mutations that are “assisted” to the surface by chemical chap-
erones,pharmacologicstrategiestoactivateCFTRchannelactiv-
ity (i.e., “activator” therapies) may also be therapeutically bene-
ﬁcial. Compounds such as phosphodiesterase inhibitors that
increase cAMP levels or ﬂavenoid derivatives (464, 465) have
been shown to stimulate chloride conductance in airway epithe-
lium cells. Drug discovery for other CFTR channel activators
by high throughput screening using cell-based ﬂuorescence
assaysarecurrentlyinprogress(466).Therehavebeennohuman
trials of channel activators completed and published.
Bypassing dysfunctional CFTR—activation of alternate chan-
nels. Dysfunctional CFTR in respiratory epithelium is associated
with both increased sodium absorption and decreased chloride
secretion resulting in abnormal hydration of airway secretions
(64, 467). Drug therapies that do not interact with CFTR but
impact one or both of these transport abnormalities by modulat-
ing alternative chloride and sodium channels in the cell mem-
branewilllikelybebeneﬁcialforairwayhydrationandclearance.
The most well-studied sodium transport inhibitor is amiloride,
which reduces the abnormally high basal NPD measurement
observed in CF airways toward normal range after topical appli-
cationtotheapicalcellsurface(468).Althoughaerosolamiloride
appeared to slow the rate of decline in lung function (468) and
enhance mucociliary clearance (469) in two pilot studies, a larger
Phase III study was unable to conﬁrm this ﬁnding.
There have been extensive in vitro investigations of chloride
secretagogues that may circumvent the CFTR channel function
by activating calcium-regulated alternative chloride channels.
Examples of such agents include, inositol triphosphase (470),
thapsigargin (471), and triphosphate nucleotides (via the P2Y2
apical receptor) (472). There has also been recent interest in
ClC-2 channels as a therapeutic target (473). Although predomi-
nant in the developing lung, ClC-2 channels persist in adult
lung and may be activated by treatment with the protein pump
inhibitor, acid-activated omeprazole.
The alternate chloride channel activators most studied in
humans are triphosphate nucleotides. Topical nasal application
of ATP- and uridine triphosphate–induced chloride secretion in
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actinguridinenucleotide,INS365,wasfoundtobewelltolerated
up to the 40-mg dose in both adults and children in an initial
Phase I trial (474).
New Approaches to Treating P. aeruginosa Infection
Because CF lung disease is a localized mucosal infection, the
role of innate immunity and endogenous cationic antimicrobial
peptides in early infection has been a recent area of scientiﬁc
and therapeutic interest (see Innate Immunity and Persistence
of Bacterial Infections) (100). These peptides produced by
epithelial cells and neutrophils provide broad antimicrobial ac-
tivity in respiratory secretions (475, 476) and rapidly kill both
Gram-positive and Gram-negative pathogens (including P. aeru-
ginosa) by disrupting the microbial membrane or enzymatic di-
gestion of microbial structures (477). These broad ranges of
peptides have the common features of being cationic amphi-
pathicmoleculesenablingthemtobindandinsertintonegatively
charged microbial membranes (101). As a result, the activity of
cationic antimicrobial peptides is highly sensitive to the ionic
milieu of the airway surface ﬂuid where they reside. Although
there is no evidence of any deﬁciency in antimicrobial peptides
in CF, it has been hypothesized (67, 478) that either the raised
ionic content of the airway surface ﬂuid in this disorder may
inactivate these salt-sensitive peptides or the slowed mucociliary
clearance (97) may overwhelm the capacity of these molecules
to kill pathogens. For these reasons, there has been increased
interest in developing cationic antimicrobial peptides as poten-
tial antibiotic therapies for early infection (100). Treatments
havebeendirectedtotopicalapplicationsbecausethesepeptides
are involved in local response to mucosal infections. Two exam-
ples include the magainin-derived peptide, MSI-78 (Genaera
Corporation, Plymouth Meeting, PA), that reached Phase III
testing as a topical antimicrobial therapy against polymicrobic
foot ulcer infections in diabetes (479), and a protegrin-derived
peptide, IB-367, (IntraBiotics Pharmaceuticals, Inc., Palo Alto,
CA) that reached Phase III trials as a topical therapy for oral
mucositis in cancer (101). Neither product has been Food and
Drug Administration approved. IB-367 is the only cationic anti-
microbial peptide to reach clinical trials in patients with CF.
Phase I trials of inhaled IB-367 demonstrated that this peptide
was well tolerated in adult patients with CF to a maximum
tolerated dose of 30 mg, but no efﬁcacy as an antimicrobial agent
has been established (480).
Developing cationic antimicrobial peptides as therapeutic
candidates will likely be challenging. The cost of production may
prohibit commercial development (100, 101). Optimal formula-
tions for inhalation of antibiotics require a neutral pH (197) that
will likely inactivateor precipitate these highlycharged peptides.
Pathogenic bacteria such as P. aeruginosa have acquired mecha-
nisms to resist killing by these peptides (477) such as modifying
the anionic surface charge on their LPS or employing proteases
to digest these antimicrobial peptides (96, 481, 482).
Another approach to enhancing innate immunity is the use
of an inhaled osmolyte with a low transepithelial permeability
to lower ASL salt concentration and increase the activity of
endogenous, salt-sensitive antimicrobial peptides. A promising
osmolyte, xylitol, has low transepithelial permeability and has
beenshowntolowerASLsaltconcentrationinCFairwayepithe-
lia in vitro (483). A common food additive for “sugarless” chew-
inggum,xylitol,hasalreadybeenreportedtodecreasefrequency
of otitis media (484) and prevent dental caries (485).
One novel approach for prevention of initial bacterial coloni-
zation using the antiadhesive properties of dextrans has been
proposed (486). These neutral polymers of glucose have been
shown to block adherence of P. aeruginosa (487) and B. cepacia
(488) to airway epithelial cells in vitro. Aerosolized dextran has
also been demonstrated to protect mice from pneumonia due
to P. aeruginosa (489). Dextran has several additional features
that make it an attractive candidate for development as an in-
haled therapy for CF; it is inexpensive and easy to manufacture,
nontoxic, and readily aerosolized.
An in vitro study to evaluate the effect of dextran on the
rheologic properties of sputum from patients with CF demon-
stratedasigniﬁcantreductioninthesputumviscoelasticity,which
may suggest improved mucociliary and cough clearance as an
additional beneﬁt (486).
Although antimicrobial peptides may play some role in the
prevention of initial infection, there is a need to consider new
paradigms for the treatment of P. aeruginosa and the develop-
ment of new antipseudomonal antibiotics. First, it may be impor-
tant to identify and treat P. aeruginosa early in the course of lung
infection before the pathogen undergoes characteristic adaptive
changes (see Prevention of Chronic P. aeruginosa Infection).
Second, researchers must continue to deﬁne both the environ-
mental signals and the bacterial genetic regulation that occurs
during the transition from initial infection to establishment of
mucoidy, bioﬁlm formation, and chronic infection. Third, the
recent availability of the P. aeruginosa genetic sequence (139)
affords a unique opportunity for postgenomic and proteomic
studies to better understand the genetic and functional diversity
of this Gram-negative organism that permits it to accommodate
to a wide range of environments and rapidly develop antimicro-
bial resistance. With this information, new strategies for drug
development will evolve.
The CF community has made signiﬁcant strides in the past
half-century. Individuals with CF are living longer and living
better. This is primarily because of both the development of
new therapies and the application of new treatment strategies, at
times using existing agents. For the future, it will be particularly
important to develop additional therapeutic agents for CF. Key
components of this effort include federal and private foundation
supportforbasicscienceresearch,partnershipsbetweenindustry
and funding agencies, and development of a network of experi-
enced investigators to perform clinical trials in CF. These pieces
are falling into place and the future of individuals with CF looks
bright.
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